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Abstract  
Pancreatic cancer presents an increasing mortality burden, with little improvement 
in survival rates since 1970, largely because of the non-resectable status of most 
tumours at diagnosis and high rate of recurrence after resection. Currently, there are 
significant problems with accurately identifying tumour margins, both during surgery 
and through histopathology, causing limitations in clinical practice and research. This 
presents a need for clinically applicable research, to improve detection and 
differentiation of healthy and cancerous tissue in the exocrine pancreas. 
 
SPARC has been shown to play a role and be expressed in the development of 
pancreatic cancer and has recently been identified as a potential biomarker for the 
disease. Raman spectroscopy is an emerging technology, showing promise in the 
detection and surgical guidance of many cancers. There is, however, limited research 
on its use in pancreatic cancer.  
 
This study aims to investigate the utility of Raman spectroscopy in identifying and 
exploring the development of pancreatic cancer and differences between healthy 
and cancerous pancreatic tissue, which could eventually allow translation to clinical 
practice.  
 
This study identifies differences between healthy and cancerous pancreatic tissue, 
using Raman spectroscopy in human tumour resections and blood samples. 
Differences are seen due to proline and nucleic acids in fresh tissue and collagen in 
fixed tissue. It further utilises a 2D cell-line model, Raman spectroscopy and ELISA, 
providing greater understanding of the interactions between cancer and stellate 
cells, including the production of SPARC and collagen, in pancreatic cancer. 
 
This study concludes by proposing a hypothesis, highlighting the importance of 
collagen, SPARC and their potential roles in causing biochemical changes to cancer 
cells and as possible biomarkers. Overall, it demonstrates the potential utility of 
Raman spectroscopy in pancreatic cancer, providing the basis for further research 
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and translation to clinical practice, improving survival rates and reducing the 
mortality burden currently associated with the disease.  
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Chapter 1- Introduction  
1.1 Pancreatic Cancer  
Cancers of the exocrine pancreas comprise of ductal adenocarcinomas (PDAC), acinar 
cell carcinomas, solid pseudopapillary neoplasms and pancreatoblastomas, making 
up 95% of all pancreatic cancers. About 5% of malignancies occur in the endocrine 
pancreas in the form of neuroendocrine tumours.(1) PDAC is the most common form 
making up more than 80% of all pancreatic cancers.  Although a rare cancer, 
accounting for 3% of all new cancer cases in the UK, incidence rates have increased 
by 14% since 1990 and over 80% are diagnosed at a late stage.(1) It is the fifth most 
common cause of cancer related death, with mortality rates remaining at 7% and a 
10-year survival rate of less than 1%, figures unchanged since 1970.(2) (Cancer 
Research UK) 
 
1.2 The normal pancreas – anatomy and histology  
The normal pancreas is a retroperitoneal organ made up of a head, body and tail, 
which extends from the duodenum to the hilum of the spleen. The head contains an 
additional projection, the uncinate process which projects medially from the inferior 
section of the head and lies under the body of the pancreas and posterior to the 
superior mesenteric vessels.(3) The tail is the only section of the pancreas which is 
intraperitoneal, lying in the splenorenal ligament, alongside the splenic vessels.  
 
The head of the pancreas lies inferior to the origin of the coeliac axis and just 
superior to the origin of the superior mesenteric axis; both major arterial sources to 
the gastrointestinal tract.(4) The aorta and inferior vena cava pass posteriorly to the 
head of the pancreas. Lying in the curve of the duodenum it is medial to the gall 
bladder and liver and in close proximity to these organs and their ducts.(4)  
 
It connects to the duodenum via two ducts; the pancreatic duct and an accessory 
duct. The pancreatic duct empties in to the ampulla of Vater, where it joins the 
common bile duct to form the hepatobiliary duct before emptying in to the 
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duodenum. The accessory duct empties into the duodenum through the minor 
duodenal papilla lying superior to the ampulla of Vater. The minor duodenal papilla 
does not always have a working sphincter (the sphincter of Helly) and patent duct 
(the accessory pancreatic duct of Santorini). In 10% of cases, the minor duodenal 
papilla is the principal duct for drainage of the pancreas.(5) Secretions are controlled 
by the sphincter of Oddi. 
 
It receives a blood supply from the pancreatic branches of the splenic artery. The 
head has an additional blood supply from the superior and inferior 
pancreaticoduodenal arteries, which are branches of the gastroduodenal artery, a 
terminal branch of the common hepatic artery, and the superior mesenteric 
artery.(3) The body and neck of the pancreas drain into the splenic vein while the 
head drains into the superior mesenteric and portal veins. 
The head of the pancreas drains into the pancreaticoduodenal, the hepatoduodenal 
ligament, and the pre-pyloric and post-pyloric lymph nodes.(3) The body and tail 
drain into the lymph nodes around the middle colic artery and the hepatic and 
splenic arteries. Ultimate drainage ensues into coeliac, superior mesenteric, and 
para-aortic and aortocaval lymph nodes.(3, 6)   
 
At a cellular and functional level, the pancreas splits into an endocrine and exocrine 
portion. The exocrine portion consists of acini, glandular epithelial cells, which 
secrete pancreatic juice.(7) The acini cells are connected by intercalated ducts 
running into a network of intralobular collecting ducts, which in turn drain into the 
main pancreatic duct. These cells secrete pancreatic juice, composed of enzymes for 
digestion including pancreatic amylase, pancreatic lipase, various proteases and 
trypsinogen.(7) The trypsinogen is stored in zymogen granules, also found in the 
pancreas, and activated to trypsin on meeting enterokinase.(7)  
  
The endocrine portion is made up of islets of Langerhans, forming approximately 2% 
of the pancreatic parenchyma, which secrete hormones involved in digestion, 
appetite and metabolism, including mainly insulin, glucagon and somatostatin.(4) 
Several other hormone-secreting cells also exist.  
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1.3 Pathology  
1.3.1 Gross Features of PDAC  
Infiltrating ductal adenocarcinomas form white-yellow fibrotic  or sclerotic masses, 
which obscure the normal lobar structure of the pancreas whereas non-neoplastic 
lesions tend to form lobular units surrounded by grape-like clusters of acini. 
Neoplastic glands or ducts also form, ranging from well-formed glands to partially 
formed glands to focal intracellular mucin production from singly infiltrating poorly 
orientated cells to solid sheets of neoplastic cells.(8) These glands are often adjacent 
to the muscular arteries and do not contain pancreatic parenchyma, with 25% of 
head of pancreas tumours extending to the duodenal wall.(9) 20% of patients have 
multiple tumours and in advanced tumours it can be difficult to differentiate 
between the pancreas, ampulla and common bile duct as the origin of the tumour.(9) 
These factors make diagnosis of pancreatic cancer and determining the origin of the 
cancer difficult, even with histological examination and staging.  
 
The tumours have the ability to invade perineural and vascular structures, often 
growing on the intimal surface of vessels. Vascular invasion can mimic pancreatic 
epithelial neoplasia (PanIN) in almost 70% of cases and is associated with increased 
tumour size, lymph node metastasis and perineural invasion, all of which confer a 
poorer prognosis.(10) In a clinical context this is particularly important due to the 
anatomical proximity of the head of the pancreas to the coeliac and superior 
mesenteric arteries. As two thirds of PDAC tumours arise in the head of the 
pancreas, proximity to and invasion of the vascular structures may make many 
tumours unable to be surgically resected.(11)  
 
1.3.2 Histological Features of PDAC  
The nuclei of invasive PDAC cell are pleomorphic, with the area varying by more than 
4 to 1 in a single gland (8) and show visible mitotic figures and loss of polarity.(9) The 
lumen of the gland contains necrotic debris and is usually incompletely lined by 
epithelial cells; luminal contents appear to be in direct contact with the stroma. 
Glands can also be in direct contact with adipose tissue with no intervening stroma. 
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The stroma in PDAC is often abundant and highly desmoplastic. It is composed of 
mesenchymal cells, cancer associated fibroblasts, endothelial cells, ECM proteins (T1 
collagen) nerve cells, pericytes and bone marrow derived cells and immune cells. (12)   
 
In moderate to poorly differentiated tumours abortive tubular structures, abortive 
mucin production and frequent mitosis can be seen.(9) These tumours often have a 
deeply infiltrative growth pattern.  
 
Beyond the tumour mass, the background pancreas can also show signs of high 
grade PanIN, atrophic changes, chronic inflammatory infiltrate, fibrosis and ductal 
dilation, all of which are also likely signs of a pre-cancerous or stage of early 
pancreatic cancer.(9) 
 
1.3.3 Histological Grading  
PDAC can be histologically graded using a system developed by Kloppel, which 
incorporates glandular differentiation, mucin production, nuclear atypia and the 
mitotic count.(8, 13)This grading, however, has minimal prognostic significance. 
 
The TNM histological grading system is more commonly used and recommended by 
the College of American Pathologists. It is based in the extent of glandular 
differentiation ranging from G1 (well differentiated >95% tumour composed of 
glands) to G4 (minimal or no differentiation).(14-16)  
 
1.3.4 Pancreatic Intraepithelial Neoplasms (PanIN) 
PanIN is recognised as a microscopic precursor lesion to PDAC.(8) They are defined as 
neoplastic epithelial proliferation in smaller calibre pancreatic ducts and are divided 
into 3 grades (Figure 1).   
 
The existence of these precursor lesions suggests that it should be possible to detect 
and treat these lesions at a non-invasive stage before the development of an invasive 
carcinoma in an asymptomatic individual. However, as these lesions are sessile, they 
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are currently undetectable using radiographic imaging and the lack of a specific 
diagnostic biomarker renders them currently undetectable.  
 
 
Figure 1: Progression of PanIN to PDAC, image taken from Khan et  al 2017(17) 
 
1.4 Pathogenesis   
While PDAC tumours are thought to arise from PanIN precursor lesions the exact cell 
type giving rise to PDAC is currently unknown; murine models suggest both ductal 
and acinar cells could give rise to PDAC.(18) Recent literature suggests that the cell of 
origin can affect tumour development and the phenotype of the resultant PDAC. (18)  
 
It is thought that chronic inflammation may play a role in the development of PDAC, 
with activation of stellate cells and development of pancreatic fibrosis leading to an 
increase in reactive oxygen species, cytokine release and an increase in the 
regulation of pro-inflammatory transcription factors.(19) These mediators of 
inflammation induce genetic damage, cell proliferation and inhibition of apoptosis. 
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The induction of stroma formation further facilitates growth of transformed cells 
through the production of pro-invasive factors.(19)  
 
PDAC displays a strong desmoplastic reaction, with invading cancer cells releasing 
matrix metalloproteinases, which cause the release of growth factors including 
transforming growth factor B (TGF-B), fibroblast growth factors (FGF), platelet-
derived growth factor (PDGF) and insulin-like growth factor-1 (IGF-1).(12) These 
become included and stored in the stroma and the desmoplastic reaction leads to 
tumour invasion, metastasis and chemo-resistance.  
 
Following chronic inflammation, there is thought to be metaplasia of normal 
cuboidal cells lining the duct to mature squamous transitional cells. This leads to 
PanIN; sessile, non-invasive lesions which progress through a precursor stage to the 
infiltrating ductal adenocarcinoma. Acinar to duct metaplasia (ADM), also resulting 
from inflammation, can also be pre-invasive lesions leading to PDAC.(12) The 
resultant duct cells go on to form PanIN and eventually PDAC. 
 
Epithelial-mesenchymal transition (EMT), where epithelial cells attain mesenchymal 
phenotype as a result of genetic and epigenetic changes in the tumour 
microenvironment, occurring in some cancers, appears to be a pivotal event in the 
cancer progression and metastasis.(12) This mesenchymal phenotype means cells 
have improved migratory capacity, invasiveness, resistance to apoptosis and 
production of extracellular matrix (ECM).  
 
Inflammation is thought to play a role in this transition although the exact 
mechanism has yet to be understood. It is thought that the recruitment of 
inflammatory cells and formation of a reactive stroma, releases transition inducing 
signals.(12) A number of cell types within the stroma release growth factors which 
may release these signals, including cancer associated fibroblasts, of which 
pancreatic stellate cells (PSC) are the main type. The release of FGF from these 
fibroblasts is a known inducer of EMT.(12) As it is known that cancer associated 
fibroblasts and PDAC cancer cells enhance each other’s proliferation, FGF production 
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leading to EMT appears to be an event in PDAC progression and metastasis.(12) EMT 
is also thought to play a role in the development of chemo-resistance; cancer cells 
without the mesenchymal phenotype display increased sensitivity to 5-fluorouracil, 
gemcitabine and cisplatin.(12) 
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1.5 Clinical Features  
Pancreatic cancer has an insidious onset, presenting initially with non-specific 
symptoms including weight loss, anorexia and gastrointestinal symptoms, leading to 
cachexia. Painless jaundice is well known as the most characteristic sign; however, 
this is often indicative of an advanced tumour blocking the bile duct. NICE guidelines 
recommend patients are referred for urgent investigation when over the age of 40 
and presenting with painless jaundice.(20) A referral should be considered for 
patients over the age of 60 presenting with weight loss and gastrointestinal 
symptoms.(20) 
 
Recent research suggests that new onset diabetes, defined as diabetes diagnosed in 
those over 50 within 2 years of diagnosis of PDAC, is also a symptom of early 
PDAC.(21, 22) The majority of patients with PDAC were diagnosed with diabetes 
within 2 years before diagnosis of PDAC and resection of the pancreatic tumours 
ameliorates the diabetes.(21) In particular rapidly deteriorating diabetes or sudden 
onset diabetes in patients who have previously shown little sign of diabetes or 
prediabetes is more likely to be a symptom of PDAC. Although Type 2 diabetes is a 
very common pathology whereas PDAC is rare, new onset diabetes could be a useful 
marker of asymptomatic or early stage PDAC and may be an area for further 
research.  
 
Clinically, tumours are staged according to location and proximity to vessels as well 
as metastasis, which determines suitability for surgery.(22)  
 
1.6 Clinical Staging  
Pancreatic cancer is staged as stages 1 to 4. In stage 1 cancer the cancer is contained 
within the pancreas; stage 1A suggests the cancer is smaller than 2cm and stage 1B is 
cancer greater than 2cm.(14) Cancer which has progressed to grow in to the 
surrounding structures such as the bile duct or duodenum is classed as stage 2. Stage 
2A is a cancer which has infiltrated these surrounding structures but not yet spread 
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to surrounding lymph nodes and stage 2B cancer is found in local lymph nodes.(14) 
Stage 3 cancer is considered to be either unresectable or borderline resectable as it 
is locally advanced, having spread to the stomach, spleen, large intestine or larger 
blood vessels.(14) The resectability status at this stage is often dependent on which 
of these structures the cancer has advanced to, with particular importance placed on 
the blood vessels impacted. A stage 4 cancer is one which has metastasised, often to 
the liver or lungs and treatment for this is usually palliative.(14)  
 
The TNM staging can also be used and offers a similar outline of staging (Table 1).(14, 
15) 
Tumour  
T1 Cancer within pancreas <2cm 
T1A Cancer <0.5cm in any direction  
T1B Cancer >0.5cm but <1cm in any 
direction  
T1C Cancer >1cm but <2cm in any direction  
T2 Cancer with pancreas >2cm but < 4cm 
T3 Cancer advanced to local tissues but not blood vessels 
Cancer >4cm 
T4 Cancer has advanced to local blood vessels  
 
Lymph nodes   
N1 No spread to local lymph nodes 
N1 Spread to 1-3  local lymph nodes  
N2  Spread to >4 lymph nodes 
 
Metastasis  
M0 No metastasis 
M1  Metastasis to distant organs  
Table 1: TNM staging of pancreatic cancer(14, 15)  
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1.7 Risk Factors  
The development of pancreatic cancer, similarly to any cancer, is multifactorial, with 
risk factors including age and genetics. Smoking, family history, particularly of 
hereditary pancreatitis, diabetes mellitus and obesity are all well-established risk 
factors.(1, 8) It is thought that 37% of pancreatic cancer cases each year are linked to 
major lifestyle factors; smoking is linked to an estimated 29% of cases in the UK and 
obesity linked to approximately 12%.(1) Age is also a major risk factor with 80% of 
pancreatic cancers diagnosed in patients between the ages of 60 and 80.(1) Some 
medical conditions and infections, including chronic pancreatitis and diabetes, 
appear to be linked to pancreatic cancer risk, however evidence is unclear.(1) An 
estimated 4% of chronic pancreatitis sufferers will develop pancreatic cancer and 
1.34% of pancreatic cancers are thought to be attributed to chronic pancreatitis.(1) 
However the epidemiology of chronic pancreatitis is unclear, as care is often in the 
community and the disease is associated with high alcohol intake, creating a stigma 




1.8 Investigations and Diagnosis 
1.8.1 NICE Recommendations  
The NICE recommendations suggest a referral for  a computed tomography scan (CT) 
with contrast (pancreatic protocol CT) for patients over the age of 40 presenting with 
painless jaundice.(24) They further recommend considering a referral for patients 
aged 60 and over, presenting with weight loss and gastrointestinal symptoms.(20) 
Where the diagnosis remains unclear and for staging, further investigation can 
include magnetic resonance imaging (MRI), fluorodeoxyglucose-positron emission 
tomography/CT or endoscopic ultrasound (EUS), where biopsies can be taken 
through US guided fine needle aspiration or a staging laparoscopy.(24, 25)  
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1.8.2 Sensitivity and Specificity of Current Diagnostic Methods 
A recent meta-analysis has shown CT to have a sensitivity of 90%, specificity of 87% 
and diagnostic accuracy of 89%.(25) The same meta-analysis reported variation in 
the results of studies of EUS, but suggested an overall sensitivity, specificity and 
diagnostic accuracy of 91%, 86% and 89% respectively, independent of fine needle 
aspiration.(25) While CT and EUS are currently the most sensitive and specific 
methods, MRI has the greatest potential to give clinically relevant information, such 
as degree of vascular involvement and detection of metastasis, because of the 
volume of information collected.(25)  
 
Although these current diagnostic techniques show high sensitivity and specificity, 
they are dependent on patients presenting with symptoms of pancreatic cancer, by 
which time the cancer may be at an advanced stage. Further it is estimated that for 
every 2000 CT scans performed, 1 patient will develop a fatal cancer attributable to 
the CT procedure.(25) The risks associated with exposure to radiation from CT,  and 
the invasive nature of EUS, which in itself can carry a risk of pancreatitis, also mean 
that it is inappropriate to subject patients to these tests without significant clinical 
suspicion of PDAC.  
 
Moreover, the National Comprehensive Cancer Network guidelines state that where 
there is a high clinical suspicion of PDAC a non-diagnostic biopsy should not delay 
surgical resection.(22) Although EUS has the potential to be highly specific and 
sensitive when combined with a biopsy by fine needle aspiration the highly invasive 
nature of EUS and need for sedation means not all patients are fit for such 
investigation at the time of diagnosis. Therefore, decisions to proceed to treatment 
are currently largely based on clinical judgement, which may be subjective, due to 
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1.8.3 Current Biomarkers  
CA19-9 is currently the most commonly used serum biomarker in monitoring 
progression of disease and in directing diagnostic decisions. CA19-9 response after 
induction chemotherapy alongside Response Evaluation Criteria in Solid Tumours 
(RECIST), a radiologic criteria, seems useful in determining which patients with non-
progressive Locally Advanced Pancreatic Cancer should undergo exploratory 
surgery.(26) It has a sensitivity of 78.2% and 82.8% specificity.(27) However, there 
are a number of limitations preventing its use as a diagnostic marker.  While it is 
raised in PDAC, there is also significant rise in a number of other benign hepatobiliary 
conditions making it a poor diagnostic marker due to the lack of specificity.(27) 
Furthermore, it has been shown to be ineffective in detecting small malignant 
tumours, meaning in early disease it is not sensitive. As a sialylated Lewis blood 
group antigen, patients who are Lewis negative, approximately 6% of the Caucasian 
population, cannot generate the antigen and so in these patients the test could be a 
false negative.(27) CEA is the second most commonly utilised marker, with a 
sensitivity of 54% and specificity of 79%.(27) 
 
1.9 Treatment and Management 
Patients with a clinical suspicion of PDAC are initially referred for a CT scan. Where a 
mass is seen on this imaging and there is no metastatic disease, the patient may be 
considered to be a candidate for surgery.(22, 24)  Of these patients those with 
jaundice and symptoms suggestive of cholangitis or fever are initially given 
antibiotics and a self-expanding metal stent during ERCP, before a preoperative 
CA19-9 is taken.(22) Suitability for surgery is considered taking into account the size 
and location of the tumour, in particular its proximity and any contact to vascular 
structures. CA 19-9 serum levels can also provide important information with regards 
to prognosis, overall survival, and response to chemotherapy as well as predicting 
post-operative recurrence. However, non-specific expression in several benign and 
malignant diseases, false negative results in Lewis negative genotype and an 
increased false positive results in the presence of obstructive jaundice severely limit 
the universal applicability of serum CA 19-9 levels in pancreatic cancer management. 
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Notably, 6-9% of pancreatic resections are inappropriately carried out on patients 
with pancreatitis,  who have suspected pancreatic cancers, in part due to lack of 
specificity seen with CA19-9.(28) 
 
Tumours considered to be borderline resectable are first biopsied during an EUS or 
staging laparoscopy, with or without the use of intraoperative ultrasound. Where 
biopsy suggests malignancy neoadjuvant therapy, with pre and post-treatment CA19-
9 , is recommended.(22) Tumours which respond to treatment are then resected. 
Postoperatively, patients who have no signs of recurrence or metastatic disease are 
given either chemoradiation, chemotherapy alone or considered for a clinical trial, 
taking into account any previous neoadjuvant therapy.(22) Chemotherapy regimens 
include various combinations of gemcitabine or 5-fluorouracil based chemotherapy.  
 
Patients are then monitored every 3 to 6 months for 2 years and then every 6-12 
months based on assessment of symptoms, CA19-9 levels and CT scan. Patients with 
recurrent disease are considered for chemoradiation or chemotherapy or treated 
palliatively, regardless of whether the recurrence is local or metastatic.  
 
Patients deemed to have unresectable disease, either because it is locally advanced 
or metastatic, are treated palliatively. Self-expanding metal stents may be placed if 
the patient has jaundice and palliative chemotherapy is considered, based on 
performance status, defined as: ECOG 0-1 with good pain management, a patent 
biliary stent and adequate nutritional intake and patient preference.(22, 24)  
Chemotherapy regimens include treatment with gemcitabine and albumin-bound 
paclitaxel, FOLFIRINOX and other gemcitabine-based combination therapy, as well as 
treatment with other chemotherapeutic agents including capecitabine, 
fluoropyrimidine and oxaliplatin.(22)  
 
Guidelines recommend that decisions and treatment, especially of surgical patients 
are carried out under a multidisciplinary team, at institutions performing a large 
number of pancreatic resections (approximately 15-20 resections per year) due to 
the rarity of the disease.(24)  
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1.10 Factors Influencing Survival After Resection  
A number of factors have been associated with improved survival after resection of 
pancreatic cancer. Pre-operatively a lower level of tumour marker and absence of a 
biliary stent are associated with improved long term survival after resection.(29) 
Intraoperatively lack of bleeding and a reduced need for blood transfusion are also 
positively associated with survival.(29) In relation to the tumour and resection itself a 
smaller, well differentiated tumour with lower positive to negative lymph node ratio 
also improves long term survival.(29, 30)  
 
Resection status, classified by margin involvement (defined as R0, R1 and R2 by the 
Royal College of Pathologists) is also thought to have an impact on survival, although 
there is some debate in the literature about this. This may be of particular 
importance as 76% of resections have an R1 (margin involvement within 1mm) 
margin status.(31)  
 
A number of studies have found that no margin involvement (R0 resection status) 
improves overall survival after resection and is independently associated with 
improved survival.(29, 30, 32, 33) However, some more recent research has also 
suggested that microscopically positive R1 resections, do not affect survival.(31, 34, 
35) It has been suggested that the margin may influence local recurrence but has no 
impact on overall survival.(36) Survival is thought to be more likely to be associated 
with a more aggressive tumour biology and factors associated with an increased 
likelihood of metastasis.(31, 34, 36) Therefore, it is thought that an R1 resection 
status is more likely to be a marker of more aggressive tumour biology therefore 
creating an association with poorer survival, but as the cause of this is related to the 
tumour biology achieving R0 resection status through revision of a surgical margin 
may not improve survival.(34) However, all of the studies agree that R0 resection 
status should be the surgical intention.  
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Chapter 2 - SPARC- Role and potential for use as a Biomarker for 
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Abstract 
Pancreatic ductal adenocarcinoma (PDAC) presents an increasing mortality burden, with few 
of the recent developments in treatment having a significant impact on the poor survival 
rates. This is largely due to the insidious onset of the disease and difficulties in detection 
meaning most cancers are at an inoperable and so incurable stage at the time of diagnosis. 
Hence there is significant need for improvements in the diagnosis and screening of PDAC.  
Secreted protein acidic and rich in cysteine (SPARC) is a potential biomarker which appears 
to plays a role in the development of PDAC and has increased expression during the 
inflammatory stages preceding PDAC development and in the juxtatumoural fibroblasts and 
stellate cells in PDAC itself. There are a number of mechanisms identified by which SPARC 
appears to play both an anti-tumorigenic role but also influence the invasive and metastatic 
capacity of cells; features which extend to its role in PDAC. The controversial role played by 
SPARC has led to research into its role and potential as a prognostic marker and therapeutic 
target.  
 
This review outlines the role and expression SPARC in the development of PDAC and its 
potential as a prognostic marker. It uses the current knowledge around this alongside more 
recent research into the detection of SPARC as a serum marker to understand the potential 
for SPARC to be used as a measurable biomarker and its clinical application in earlier 
diagnosis or screening for PDAC.  
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Introduction  
Pancreatic cancer is the fourth most common cause of cancer related death in the 
developed world. With few specific symptoms and a lack of screening markers, 
diagnosis is often late making prognosis poor; it has an overall 5-year survival of only 
3% in the advanced stages.(1, 2) Tumours with potential for resection are found in 
only 10-15% of patients meaning that for the majority of patients the diagnosis is 
terminal and treatment is palliative.(1) Amongst patients who do have resectable 
tumours, recurrence is a significant problem, with one study suggesting disease free 
survival at 8 months was only 50% (37) and 95% of recurrences occur within 2 years 
of resection.(38) 
 
Symptoms for pancreatic cancer include loss of appetite, change in bowel habit and 
nausea, with jaundice being a later sign. The insidious onset of these relatively non-
specific symptoms combined with the fact that pancreatic cancer is quite rare, 
means patients often present late. As well as this, investigations for pancreatic 
cancer include computer tomography (CT) imaging and endoscopy which are invasive 
and carry risks of high exposure to radiation. Hence, in accordance with NICE 
guidelines, doctors rarely refer patients for CT investigation until they present with 
painless jaundice, which is often indicative of an advanced tumour with little 
possibility of resection. Therefore, diagnosis of pancreatic cancer is often in the very 
late stages of the disease.  
 
Risk factors for pancreatic cancer are also somewhat non-specific, with increasing 
age, obesity and high alcohol intake being the most common. Diabetes mellitus is 
also a major risk factor, associated with a 1.8-fold increased risk of pancreatic 
cancer.(1) Chronic pancreatitis is thought to be a potential precursor, however, even 
this condition is extremely rare and not present in a significant number of those 
diagnosed with pancreatic cancer.  An estimated 4% of chronic pancreatitis sufferers 
will develop pancreatic cancer and 1.34% of pancreatic cancers are thought to be 
attributable to chronic pancreatitis.(1) The epidemiology of chronic pancreatitis is 
however unknown, as care is often in the community and the disease is associated 
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with high alcohol intake, creating a stigma which makes identifying and following 
patients up difficult.(23)  
 
There has been some research on potential biomarkers for pancreatic cancer, with a 
number of recent reviews on the role and potential for various biomarkers to be 
used to predict prognosis.(39-42) Many of these reviews focus on the potential for 
these biomarkers to be used as a therapeutic target.  
 
However, the delay in presentation, investigation and diagnosis of pancreatic cancer 
has led to a lack of knowledge about the pre-cancerous or early stages of the 
disease. There is therefore a need to consider how the current knowledge base could 
be used to consider avenues for research into the earlier detection of pancreatic 
cancer. This increased knowledge base, would be imperative in improving prognosis 
as resection is currently the only truly curative treatment. 
  
Osteonectin or secreted protein acidic and rich in cysteine (SPARC) is a potential 
biomarker with extensive research into its role, ability to predict prognosis and 
potential as a therapeutic target.(39, 43) However, more recently there has been 
some work to suggest it may be present in early disease and its expression in various 
stages of pancreatic cancer and chronic pancreatitis has been investigated as well as 
its presence in bodily fluids. This newer area of research suggests potential avenues 
for SPARC to become a measurable biomarker with the possibility to lead to a role in 
earlier diagnosis.   
Aim 
This review outlines the role and expression of SPARC in the development of 
pancreatic ductal adenocarcinoma. It then considers its potential role in predicting 
prognosis of PDAC both in patients who have and have not received chemotherapy. 
It also examines the potential for SPARC to be measured as a serum marker, looking 
at potential clinical applications and limitations in detection methods, with a view to 
understanding the potential for SPARC to be used as a measurable biomarker in 
diagnosing or screening for PDAC.  
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Secreted Protein Acidic and Rich in Cysteine  
SPARC is a calcium-binding, matricellular protein, which interacts with the 
extracellular matrix.(44) It is described as a non-structural or matricellular protein; a 
protein transiently secreted to control cell function and interactions between cells 
and the extracellular matrix. (45) In healthy tissue it is expressed in embryogenesis, 
bone and platelets, appearing to be a marker for activated fibroblasts (44) and has a 
role in cell migration, proliferation and invasion.(44, 46, 47) It is ordinarily rapidly 
degraded by various proteases, preventing its accumulation in the extracellular 
environment.(45) While its proteolysis can be initiated by matrix metalloproteinases 
(MMP), SPARC is also able to regulate MMP activity during inflammation and tissue 
remodelling.(45)  
 
The SPARC gene is located on human chromosome 5q.(45) The protein structure is 
divided into 3 domains; the calcium binding N-terminus acidic domain and C-
terminus extracellular domain which bind calcium with low and high affinity 
respectively and the follistatin-like domain, which is rigidly stabilized by five 
disulphide bonds and contains a b-hairpin subdomain.(45) Of these, the C-terminus 
domain is particularly important in SPARC’s function in modulating angiogenesis, 
inhibiting vascular endothelial growth factor (VEGF), b-fibroblast growth factor 
(bFGF) and platelet derived growth factor (PDGF), in turn inhibiting endothelial cell 
stimulation and so angiogenesis. (45, 48) 
  
Expression of SPARC in PDAC 
Where it has been identified in PDAC, it is primarily expressed in the juxtatumoural 
fibroblasts(49) and pancreatic stellate cells and its presence here has been shown to 
suggest a poorer prognosis for these patients.(44, 50)  There may also be some 
expression in the pancreatic cancer cells and surrounding endothelial cells although 
there remains some debate as to the expression of SPARC in the cancer cells lines in 
the primary tumour.(47, 49) However, in metastatic PDAC there is greater agreement 
that the expression is predominantly in the surrounding stroma.(47)  
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In a comparison of the roles of osteopontin and SPARC, osteopontin expression was 
increased in tumour cells and was also increased in tumour cells which had 
metastasised to the liver, suggesting it has a clear role in the promoting the growth 
of cancer cells in PDAC.(51) SPARC expression, however was more limited to the 
adjacent extracellular matrix as well as in the fibroblasts and endothelial cells and 
was thought to have an anti-tumorigenic effect on cancer cells expressing SPARC 
mRNA.(51) 
  
The expression of SPARC in chronic pancreatitis, thought to be a precursor to PDAC, 
has also been investigated. This may give some insight into the early activity of 
SPARC and early changes which occur, including some of the precancerous changes. 
Interestingly, SPARC expression was found in 62% of chronic pancreatitis samples, 
but with little expression in malignant cells.(50) It was found that SPARC is transiently 
upregulated, with increased expression exhibited in the basal membrane of  acinar 
cells, in acinar destruction and is only activated or synthesized during inflammation, 
in a rat model.(52) It is subsequently lost in the final stages of acinar destruction and 
during acinar to duct metaplasia, also an event known to preceed PanIN and PDAC, 
suggesting the SPARC expression is lost with the loss of acinar characteristics in a 
cell.(52) In the late stages of chronic pancreatitis, potentially immediately before or 
concurrent with the very early development of PDAC, there is some SPARC 
expression in stellate cells. (52) This corresponds with the observation that in PDAC, 
SPARC expression is primarily in the stellate cells of the stroma, with a lack of 
expression in the cancer cells.(50, 53) Hence, there may be potential for SPARC 
expression in these stellate cells to be used as a screening or diagnostic marker for 
early PDAC, especially in those with chronic pancreatitis.  
 
In one study showing a lack of expression in pancreatic cancer cell lines, the aberrant 
methylation status of SPARC correlated with lack of expression, suggesting that DNA 
methylation is a mechanism for silencing of SPARC.(49) A further study showed this 
aberrant methylation to also interfere with tumour stromal interactions.(54) It was 
found to be a common feature of intraductal papillary mucinous neoplasms, thought 
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to be a non-invasive neoplastic precursor to PDAC,  and to increase with histological 
grade.(54)  
 
Methylation and Cell Cycle Mechanisms 
More specifically hypermethylation peaks were found in the CpG sites 1 to 7 and CpG 
sites 8-12.(55) These appear to gradually increase from normal to chronic 
pancreatitis to the adjacent normal to pancreatic cancer tissues.(55) Of these, 
aberrant methylation of sites 8-12 in pancreatic cancer patients was significantly 
increased compared to the normal and an event thought to occur early in the 
development of pancreatic cancer tumours.(55) Furthermore, a larger tumour size 
was associated with, and shown to be a contributor to, an increase in methylation of 
sites 8-12.(55) Hence, hypermethylation of this region may be a potentially sensitive 
marker in high risk patients prior to the development of symptoms. While this 
supports the premise of SPARC as a tumour suppressor gene and adds to our 
knowledge of the role of SPARC in pancreatic cancer, a gap remains for there to be a 
more clinically applicable understanding. Much of the current research is conducted 
on pancreatic tissue and tumours themselves, while there is a need to detect a 
biomarker in a form that could be accessed and measured in a less invasive manner. 
To confirm hypermethylation as a change specific to pancreatic cancer, methylation 
in white blood cells in healthy volunteers was compared to that in pancreatic 
tissue.(55) However, it may be interesting to extend this to detecting 
hypermethylation of these CpG sites in the blood of patients with pancreatic cancer, 
as it would give further insight into its potential as a more clinically measurable 
marker of early PDAC. 
  
While SPARC has previously been suggested to be a target for aberrant methylation 
and shown to have growth-suppressive activity, further work has been done on the 
mechanism of SPARC inhibiting the growth of human pancreatic cells. SPARC was 
shown to be highly expressed in the extra-cellular matrix components but rarely 
expressed in the cancer cells themselves.(56) Forced expression of SPARC was shown 
to inhibit cell proliferation in vitro whereas knockdown promoted growth and colony 
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formation, suggesting SPARC may be a tumour suppressor in pancreatic cancer.(56) 
Furthermore,  this appeared to be associated with G0/G1 arrest, by inhibiting G1/S 
transition in the cell cycle but without inducing apoptosis,(56) as a result of the 
upregulation of both p53 and p27kip1, which are related to G1/S cell cycle arrest.(56)  
SPARC-mediated apoptosis has, however, been reported, by activating the extrinsic 
pathway via caspase 8.(48) Specifically, the N-terminus engages in this mechanism 
leading to apoptosis while inhibiting angiogenesis, whereas the other domains 
appear to have little activity. More importantly it was shown that the N-terminus 
increased chemosensitivity of the cells by augmenting apoptosis, through interfering 
with an interaction between caspase 8 and Bcl2, even in refractory cells. 
   
Role of SPARC in Cancer  
SPARC has been shown to play a controversial role in the context of cancer. Much of 
the literature suggests it has an anti-tumorigenic action on the cancer cells 
themselves. In a cell panel it was shown that cells expressing SPARC mRNA were 
unable to grow in vivo, possibly due to the increased expression of p21 in response 
to SPARC, leading to growth arrest.(51) This supports the premise of SPARC having 
anti-tumorigenic properties in the context of PDAC,(51) and corroborates an in vitro 
study showing exogenous SPARC supresses the growth of pancreatic cancer cells.(49) 
However, its expression and role in the extracellular matrix is one influencing 
invasion and metastasis of the cancer cells. In a number of cancers, SPARC has been 
shown to influence the invasive and metastatic capacity of cells in both human and 
mouse models, and this appears to extend to PDAC.(47) Tumours expressing SPARC 
have been suggested to be more advanced and likely to metastasise.(50)  
Tumour protein 53 induced nuclear protein 1 (TP53INP1), a pro-apoptotic stress-
induced p53 target gene has also been shown to modulate cell migration by 
regulating SPARC expression.(57) TP53INP1 is able to reduce SPARC expression in 
vitro.(57) A loss of TP53INP1 expression early in the formation of pancreatic tumours 
is thought to be in part responsible for the strong metastatic phenotype of 
pancreatic cancer.(57) Hence, a loss of TP53INP1, inducing expression of SPARC, 
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could lead to the increase in migration and metastatic capacity of pancreatic cancer 
cells.(57) 
 
It has been suggested that SPARC and tumour growth factor-b participate in a 
feedback loop, where SPARC induces the expression of TGF-b and TGF-b reduces the 
expression of SPARC, with the two influencing each other’s production.(47) However, 
the mechanism for this induction is currently unknown. 
  
Furthermore, exogenous SPARC treatment has been shown to increase the invasive 
capacity of cells, in vitro, potentially due to the induction of expression of MMP-2 in 
PDAC.(47) It has been hypothesized that SPARC and MMP-2 may participate in a 
positive feedback loop, where SPARC stimulates MMP-2 and this then cleaves SPARC, 
increasing its affinity for collagen and localising it to the basement membrane.(47) 
This appears to be directly linked to the development of the desmoplastic reaction in 
PDAC,(47) which encourages tumour invasion, metastasis and chemoresistance.(58)  
As PDAC displays one of the most prominent desmoplastic stromal reactions of all 
carcinomas, (58, 59) and SPARC has been shown to play a significant role in the 
development of this reaction and is found highly expressed in the tumour stroma, 
further work looking at its expression in pancreatic juice or other bodily fluids may 
give some basis to consider it a measurable biomarker, bridging the link to clinical 
practice. 
   
SPARC expression as PDAC progresses has also only recently been investigated. The 
normal pancreas has little normal stroma, however this forms as neoplastic lesions 
develop and extensive stroma formation is associated with invasive carcinoma.(53, 
60, 61) It was observed that there is no SPARC expression in the normal pancreas but 
this expression arises in invasive PDAC and remains throughout metastasis, although 
in concordance with other studies it is restricted to the stroma of the tumour.(50, 53) 
It was further shown to be an independent prognostic factor in resectable pancreatic 
cancer.(53)  
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Prognostic Role of SPARC  
The significance of the pancreatic tumour microenvironment; the role of the stroma 
as well as SPARC are considered to play an important role in tumour progression. The 
limited effectiveness of chemotherapeutic agents targeting cancer cells in PDAC has 
increased interest in the stroma as a potential therapeutic target.(59) The stroma is 
further thought of as a mechanical barrier, preventing drug penetration which may 
contribute to the often poor response to chemotherapy.(62) SPARC expression in the 
stroma of pancreatic tumours has been shown as a predictor of poor overall survival 
(50, 51) as well as being a potentially prognostic marker for the effectiveness of 
chemotherapy.(63)  
 
The stroma itself was also initially associated with a poor prognosis,(60) although 
some more recent studies suggest the stroma may also have a protective role.(45, 
59, 64) Hence, stroma depletion could be problematic where it occurs as a result of 
drug delivery, particularly where SPARC is the therapeutic target.  As SPARC is 
antitumorigenic, depleting stroma, and so SPARC may cause an increase in 
proliferation of cancer cells. More so, where SPARC plays a role in delivering the drug 
to the cancer cells, depleting the stroma also depletes the carrier and so reduces 
drug delivery. 
  
Tumour stromal interactions have been shown to promote invasion and 
metastasis.(60, 65) This occurs due to cancer cell derived MMPs releasing growth 
factors, which become isolated in the stroma. Further interaction of these growth 
factors with insulin and their correspondent receptors promotes cancer cell 
proliferation. Production of Cox-2 and VEGF-1 then encourages epithelial-
mesenchymal interactions, making surrounding tissue more susceptible to 
invasion.(60)  
 
However, recent experimental models have demonstrated that the tumour stroma 
may restrain tumour growth.(59) In the normal pancreas, stellate cells play a role in 
the repair of pancreatic injury, producing the extracellular matrix proteins. Whereas, 
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in chronic pancreatitis and pancreatic cancer prolonged activation of the stellate cells 
is a key player in pancreatic fibrosis and tumour desmoplasia.(65) Some reports have 
suggested that this fibrosis could play a role in restricting tumour growth. (59, 64) 
It could therefore be hypothesised that stroma production may be  defensive 
mechanism in response to the proliferation of cancer cells, in order to reduce their 
rate of growth. While it may be somewhat successful in doing this, it also appears to 
have an impact on the surrounding healthy tissue, making it more susceptible to 
invasion. Therefore, although there may be some inhibitory effect on the rate of 
growth of the tumour, this is counteracted by a simultaneous increase in 
susceptibility to invasion. Hence, the stroma may have a protective role, but still be 
associated with a poor prognosis. Where there is greater proliferation of cancer cells, 
there is a dependent increase in stroma production, and so a greater resultant 
impact on the surrounding tissue.  
  
Moffitt et al classified stroma as ‘normal’ and ‘activated’, with the activated type 
expressing a more diverse set of genes associated with macrophages and proteins 
including SPARC, suggesting a more complex model of stroma in PDAC.(66) It was 
hypothesized that only activated stroma may be responsible for disease 
progression.(66) Furthermore, two-tumour specific subtypes of PDAC were classified, 
with basal like subtypes conferring a poorer prognosis than the classical subtype.(66)  
It was further shown that while SPARC expression is higher in the intratumoural 
stroma of PDAC, and this expression has been associated with reduced overall 
survival, the presence of cancer associated fibroblasts themselves was not associated 
with a poor prognosis.(59) It was shown that cancer associated fibroblasts are a 
heterogeneous population, with distinct functions, although the variety in this 
population and these functions are not yet clearly understood. (59) It is therefore 
possible that an increase in certain fibroblasts with the population, expressing 
certain proteins, for example SPARC, may show different survival patterns and this 
may warrant further investigation. Another recent study found there was no 
significant negative association between increased stromal SPARC expression and 
overall survival.(67) The exact function and interaction of each of the stromal 
components is not yet completely understood and clinical trials for stromal depletion 
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in PDAC have failed, making it difficult to draw clear conclusions on the role of the 
stroma.(67) 
 
SPARC expression in the stroma has previously been shown to be a predictor of poor 
prognosis,(44, 50, 53, 61, 65, 68), independent of any adjuvant treatment.(53) In 
particular, greater expression of SPARC in the more distal stromal cells correlates 
with poorer overall survival and more nodal metastases.(65) One very recent study, 
using 73 patients suggested this expression may also have a potential role as a 
marker in predicting lymph node metastasis and has been suggested to be more 
sensitive and specific for this than CA19-9.(61) However, further work is needed to 
determine the validity of the results, both due to the retrospective nature of the 
study and use of immunohistochemical staining which the authors believe is 
insensitive for protein detection. 
  
SPARC expression has further been investigated to understand its value in predicting 
the efficacy of chemotherapy. Its impact on overall survival and prognosis with 
different regimens of chemotherapy is conflicted in the literature. Combination 
treatment of gemcitabine with nab-paclitaxel has recently been approved for the 
treatment of metastatic pancreatic cancer. Nab-paclitaxel is a nanoparticle sized 
albumin-bound taxane.(62) It is thought that through an albumin-SPARC interaction, 
stromal SPARC facilitates the accumulation of albumin in the tumour.(62, 69) Hence, 
SPARC is thought to have a potential role as a predictive marker for the combination 
treatment, partly as it increases the delivery of the chemotherapeutic agents to the 
tumour cells as well as having its own anti-tumorigenic mechanisms.(70)  
 
However, a phase III metastatic pancreatic adenocarcinoma clinical trial (MPACT) 
comparing nab-paclitaxel plus gemcitabine vs gemcitabine alone suggested that 
SPARC is not an independent predictor of overall survival or of nab-paclitaxel 
efficacy.(71) The MPACT trial used tissue samples from metastatic lesions or samples 
of unidentified origin, with only 11% of samples as confirmed pancreatic lesions, (71) 
whereas previous trials were conducted on resected primary PDAC tumours. A 
further study, observed that the kind of tissue origin (primary vs metastatic) may 
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have a significant impact on the value of the biomarker and this may be an important 
consideration in the design of future trials.(67) 
 
For treatment with adjuvant gemcitabine alone after resection it has been shown to 
be a negative predictive marker for response to chemotherapy with gemcitabine.(67, 
70) This is despite the fact that in vitro studies have shown that overexpression of 
SPARC enhances the inhibition of cancer cell proliferation, by enhancing the impact 
of gemcitabine though an increase of apoptotic signals and the induction of G0/G1 
arrest causing apoptosis.(72) It is hypothesized that this may be because an 
increased stromal SPARC expression may be due to a more dense stroma and this 
denser stroma could present a more significant treatment barrier.(67) Therefore, 
although SPARC may enhance gemcitabine induced apoptosis, the stromal 
components producing SPARC may prevent the drug from effectively penetrating the 
tumour to exert these effects.  
 
While SPARC expression as a predictive marker for chemotherapy as well as its 
potential as a therapeutic target is well described in the literature, at present the 
impact of chemotherapy in PDAC is limited largely by the fact that most patients 
present with very advanced disease. Chemotherapy with gemcitabine alone 
increases median overall survival to 6.6 months and the addition of nab-paclitaxel in 
metastatic disease further increases this to 8.7 months.(62) Although this is a great 
improvement in comparison to no treatment, the prognosis for most patients is still 
poor and chemotherapy is largely considered to be palliative. In addition, the 
majority of patients present with advanced tumours which are non-resectable, which 
further limits the efficacy of chemotherapy and prevents any treatment from being 
curative. Hence, the need for a method of early detection, or a screening marker, of 
pancreatic cancer is paramount, to allow the cancer to be detected at a stage where 
there may be potential for a cure and so significantly improving prognosis. 
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Early detection  
There is limited literature on a potential marker that could be used for screening for 
PDAC. There are however, some small studies on the detection of SPARC in the 
serum of patients with PDAC, although there is little concordance in their 
findings.(47, 49, 73, 74)  
 
Of the four studies that have attempted to measure SPARC as a serum marker, Sato 
et al found no significant difference in the mean SPARC level in the serum of patients 
with PDAC against controls.(49) Guweidhi et al, on the other hand found lower 
serum SPARC in patients with PDAC against controls,(47) whereas most recently 
Papapanagiotou et al found higher serum SPARC in patients with PDAC. Furthermore, 
the latter found an association between tumour size and the serum SPARC level, 
within PDAC patients, although there was no comparison between the amount of 
SPARC measured in the tumour and serum.(74)  
 
There were some differences in the methodology of the studies, which may account 
for some of the differences in results. Whereas Guweidhi et al looked for a 
correlation between SPARC mRNA levels in tissue and serum SPARC levels, and found 
no correlation, the correlation in Papapanagiotou et al’s study was found between 
tumour size and serum SPARC levels. Differences in matching patients and 
comparison groups, with only Papapanagiotou at el’s study matching according to 
confounding variables, may also account for some of the differences in the results of 
the 3 studies.(74)  
 
Sato et al’s study showed no differences in serum SPARC levels between patients 
with and without PDAC, although this may be because samples of tissue and serum 
samples were not taken from the same patient.(49) Therefore, although there is a 
comparison made between disease types, any correlation between tissue and serum 
SPARC levels can’t be measured. Furthermore, neither intrapatient nor interpatient 
variability have been accounted for. 
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However, the results of Papapanagiotou et al’s study may also need to be 
interpreted cautiously due to the small sample size, especially when considering the 
correlation between tumour size and SPARC levels; 15 patients had a diagnosis of 
PDAC and these patients were categorised according to tumour size, meaning there 
were very few patients in each of the tumour stage classes, although the results 
were statistically significant.(74) 
 
Another recent study showed that, in the healthy individuals, BMI correlated with 
systemic levels of SPARC, associated with higher number of bone marrow-derived 
stem cells in peripheral blood, which are known to be involved in the pathogenesis of 
obesity-associated cancers, of which PDAC is one.(73) However, it was found that 
mean plasma levels of SPARC were significantly lower in patients with PDAC 
compared with healthy controls, in line with Guweidhi et al’s findings, as was the 
SPARC/osteopontin ratio, (73) although only SPARC/osteopontin ratio correlated 
with BMI and this is thought to contribute to the systemic spread of the tumour.  
It is hypothesized that the lack of association between levels of SPARC and BMI may 
be due to the increased production of SPARC by fibroblasts in the extracellular 
matrix. (73) Overall this provides a basis for further clinical studies looking at plasma 
levels of SPARC in patients with PDAC as well as further work looking at the influence 
of the desmoplastic fibrotic environment and metabolic activity of stromal cells on 
SPARC levels in patients with PDAC. 
 
In line with these studies, it could be hypothesized that as SPARC expression appears 
to be closely linked with prognosis and expression appears to arise with the 
development of PDAC, there is potential for SPARC to be used as a screening marker, 
although the serum levels of SPARC that may be significant and any correlation with 
tumour grading has yet to be determined. Furthermore, SPARC is expressed in 62% 
of chronic pancreatitis samples,(50) thought to be greatest risk factor and a potential 
precursor for the development of PDAC.(75) Therefore, if there is a continuum from 
chronic pancreatitis to the development of PDAC, the expression of SPARC may 
correlate and this could be used to identify a clinically significant value as a potential 
marker. However, difficulties in detecting SPARC at low quantities remains an 
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obstacle and improving methods of detection may go some way to developing a 
screening method. 
  
Papapanagiotou et al’s study suggested enzyme linked immunosorbent assay (ELISA) 
could be used as a method of detecting SPARC, with a detection range of 0.78ng/ml 
to 50ng/ml with a minimum detection concentration of 0.195ng/ml.(74) It is the first 
paper to propose a potentially clinically relevant cut-off point, suggesting serum 
values higher than 100.18ng could be used to predict pancreatic cancer. However, 
the difference between T1/T2 tumour groups and the control group was only 
marginally significant, which might suggest using this cut-off value might not be 
sufficiently sensitive in detecting early stage cancer.(74) On the other hand the 
authors suggest that a larger study, with more participants may be helpful in 
establishing this difference.(74)  
 
Some studies have also shown potential for urine to be a source of possible 
biomarkers for pancreatic cancer, although the studies are very small and the 
literature is limited.(76-78) Urine biomarkers have shown potential in being able to 
differentiate chronic pancreatitis from pancreatic cancer,(76-78) which could be 
clinically useful in diagnosis and screening. This suggests urine could be a potential 
source of a biomarker for diagnosis or screening in pancreatic cancer, and further 
work to detect expression of SPARC in the urine may be of value. Although high 
SPARC expression has been detected in PDAC there is currently no literature about 
how it may be excreted. 
  
A key difficulty in early detection however, may be that the exact cell type that gives 
rise to PDAC is unknown.(60) There is some evidence to suggest that intraepithelial 
neoplasms(60) and intraductal papillary mucinous neoplasms(54) may be non-
invasive precursor lesions but identifying the initial cell type undergoing metaplasia 
would be imperative in allowing for further work in identifying a screening or 
diagnostic marker. The lack of information about SPARC expression in these 
precursor lesions, especially in those studies attempting to measure SPARC as a 
serum marker, where no patients with such precursor lesions were used is a further 
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limitation to all of these studies. The lack of knowledge regarding initial cell type 
creates a difficulty in research in looking for an early biomarker and further 
knowledge in this area may be a basis to investigate SPARC expression in pre-invasive 
neoplastic lesions. 
  
The value of early screening may also be questionable due to the high rate of 
recurrence even amongst patients who have resection. However, at present 
resection, where possible, offers the best prognosis; where the overall 5-year 
survival is less than 5%, this can be up to 30% in those who have surgical resection 
with adjuvant chemotherapy.(76) As recurrence is a significant problem in long term 
prognosis,(37, 79) identifying any association between SPARC expression and the 
likelihood of recurrence after resection would also be of value, alongside further 
work into the potential for SPARC to be used in early detection, possibly as a serum 
marker.  
 
Risk factors and links to SPARC 
A further difficulty in screening may be that PDAC is so rare with an estimated 
lifetime risk of 1 in 70. (2) (Cancer Research UK). While there has been an increase in 
incidence of 15% since 1990, potentially due to the increase in the ageing 
population, it accounts for 3% of the all cancer diagnoses in the UK.(1, 2) Therefore, 
even where a highly specific and sensitive biomarker for pancreatic cancer could be 
found, screening the general population may not be practical or cost effective. Risk 
factors for pancreatic cancer are also broad, with age being the greatest risk factor, 
making it difficult to determine who a screening marker should be aimed at. Hence, 
where a potential screening marker or test could be found, further determining who 
to screen for the disease would be a clinically important consideration and potential 
avenue for research. 
  
Having a sensitive and specific biomarker could, however, be useful in aiding 
diagnosis as even the gold standard CT imaging at present can misdiagnose benign 
lesions as malignant ones leading to some patients undergoing unnecessary surgery. 
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Moreover, the current guidelines suggest that a negative biopsy is not necessarily a 
reason to delay resection, where clinical suspicion of PDAC is high. Therefore, a 
marker for pancreatic cancer, would be valuable in both identifying the disease 
earlier and reducing misdiagnosis.  
 
Research suggests there may be some links between levels of SPARC and risk factors 
for PDAC, including obesity and diabetes. As the knowledge base around these links 
increases, subgroups within these risk factors may form potential screening criteria, 
especially when using SPARC as a biomarker. As well as this the link between these 
risk factors, SPARC expression and PDAC may give new insight into the role of SPARC 
and these risk factors in the pathogenesis of PDAC. 
  
Obesity is also considered to be a significant risk factor for PDAC and there is some 
literature to suggest a link between SPARC expression and obesity. SPARC expression 
in adipose tissue is increased by high levels of insulin and leptin, and weight loss was 
shown to reduce SPARC levels.(80, 81) It seems likely that SPARC has a role in the 
development of obesity related complications although its contribution to the 
association between obesity and cancer has yet to be understood.(81) 
 
In diabetes, it is proposed that SPARC is secreted by stromal cells and regulates B cell 
response to growth factors.(80) Stromal SPARC expression in the pancreas could be 
regulated by the metabolic parameters and so be induced in type 2 diabetes, 
potentially contributing to the risk of pancreatic cancer.(80)  
Conclusion  
SPARC is a matricellular protein involved in cell migration, proliferation and invasion. 
As such it plays a role in the development of a number of cancers. In PDAC its 
expression has been described primarily in the tumour stroma, where it is thought to 
have an anti-tumorigenic impact on cancer cells. Expression is upregulated during 
inflammation, which is thought to be part of the aetiology of PDAC. It is then 
downregulated during metaplasia of cells. Hence, SPARC is expressed in and plays 
some role in the development of PDAC.  
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Aberrant DNA methylation appears to be a mechanism for this downregulation and 
interference in tumour stromal interaction. A number of cell cycle mechanisms have 
been suggested as methods by which SPARC inhibits cell proliferation including by 
inducing G1/S transition and induction of apoptosis. 
  
Despite having an antitumorigenic role, SPARC has also been shown to be linked to 
the desmoplastic reaction in PDAC, due to interactions with TGF-b and MMP2. It is 
possible that stroma and SPARC production is a defence mechanism to cancer cell 
proliferation, but counter-productive as it simultaneously increases tumour invasion 
as a result of its impact on surrounding tissue. The relationship between SPARC and 
PDAC is clearly complex and further work may be needed to understand interactions 
between components of the stroma, SPARC and the surrounding tissue, to determine 
the extent to which these make healthy tissue vulnerable to invasion compared to 
their potential ability to reduce the rate of tumour growth.  
 
While SPARC has been widely researched as a therapeutic target, literature is still 
undecided on how useful a predictive marker it is for the efficacy of chemotherapy. 
However, given so many patients only receive chemotherapy as palliation, 
understanding SPARC’s role and expression with a view to determining its potential 
as a detectable diagnostic or screening marker, may be more clinically beneficial. The 
literature on this is however much more limited and conflicted.  
 
The recent work around detecting SPARC as a serum marker and its associations with 
risk factors for PDAC suggest that it may have the potential to be used as a 
biomarker. Further work understanding these associations may also be helpful in 
developing a clinical aid for deciding in which patients SPARC would have greatest 
utility as a screening marker and how results could be interpreted in the context of 
other clinical factors. This further and more clinically applicable work will give 
potential to find a biomarker for PDAC, which will play a significant role in improving 
diagnosis, screening and ultimately improving the survival rate of PDAC. 
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Chapter 3 - Emerging Methods in Detection and Diagnosis  
3.1 Raman Spectroscopy  
Raman spectroscopy is a technique used to understand the chemical fingerprint of a 
substance by analysing the scattered light emitted due to molecular vibrations. This 
is similar to infrared spectroscopy, however a change in molecular polarisability is 
required for the Raman effect. Hence, some vibrations can be measured using 
Raman spectroscopy, which are undetectable in the infrared spectrum and vice 
versa.   
 
When light, usually from a monochromatic laser, is directed at a substance the 
majority is either absorbed, reflected or unchanged in energy, known as Rayleigh 
scattering. However, a small amount of light changes in frequency when absorbed 
then emitted, as it interacts with molecular bonds, which vibrate due to the energy 
given to the sample, as photons exchange part of their energy with the molecular 
bonds in the substance.(82, 83) This is known as Raman scattering, which occurs in 
less than 1% of photons that interact with the molecules.(83)  
 
As each molecular bond has a unique vibration the resultant scattering process is 
unique to the bond.(82)  Thus, by understanding the vibration of each bond and 
measuring the energy change in the Raman scattered light it is possible to 
understand the chemical composition of a substance. The wavelength at which the 
Raman scattering occurs can be affected by the strength and configuration of the 
bond, giving information about the overall compound. The measurements are 
depicted on a graph as Raman spectra, with the intensity of the scattered light on the 
y-axis and each wavenumber  on the x-axis.  
 
The spectrum gives information about the chemical composition of the material 
through the location of the Raman bands. Stresses in the sample, variation in 
crystallinity or the amount of the material, relative to a band shifting, narrowing or 
broadening or variation in intensity respectively, can be detected.  
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3.2 Surface Enhanced Raman Spectroscopy  
As Raman scattering is an inefficient process, mostly because the Raman signal is 
significantly less powerful than the fluorescence signal, it can be useful to enhance 
the scattering intensity to provide greater sensitivity. The surface enhanced Raman 
spectroscopy (SERS) technique can be applied for this purpose. SERS uses 
nanoparticles of noble metals,  silver, gold or copper, to enhance the signal at the 
surface, giving a sensitivity 6-10 orders in magnitude greater than conventional 
Raman spectroscopy.(82, 83) Nanoparticles of noble metals are most suited for use 
in biological samples due to their chemical inactivity and optical properties, allowing 
amplification of the Raman signal when introduced into cells, without changing their 
chemical composition.(82, 84) 
 
The amplification of the Raman signal is achieved by two mechanisms; the 
interaction of electromagnetic waves with nanoparticles with dimensions smaller 
than the wavelength and the chemical interaction between the molecule and 
nanostructures surface. The electromagnetic mechanism is the excitation of a 
propagating surface plasmon polariton mode, occurring at the interface between a 
metallic waveguide and a dielectric. (84) For this enhancement to occur, the 
molecule needs to located close to the metallic surface at hotspots.(84) The chemical 
enhancement occurs when there is the formation of a charge-transfer state between 
the nanoparticle and molecule, which can be resonantly excited leading to a 
resonance Raman enhancement. (84)  
 
SERS can be employed using two methodologies in biological application. Label free 
detection enhances the intensity of the overall intrinsic chemical fingerprint, through 
the analysis of the direct interaction between the samples and nanoparticles.(84) 
Indirect detection can also be used, allowing single molecule detection, through the 
use of SERS tags labelled with Raman reporter molecules with distinct signals.(84) 
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3.3 Advantages and Disadvantages  
Raman spectroscopy is a useful technique allowing for analysis of a wide range of 
materials. As a non-destructive technique that does not face interference from water 
molecules it is particularly useful in biological applications and means little sample 
preparation is required.(83, 85) Hence results are more representative of in vivo 
conditions and Raman spectroscopy has been widely explored for its potential in 
biomedical exploration.(85, 86) The technique also has the potential to be used 
safely in vivo, allowing for future use as a potential diagnostic or intraoperative 
technique.(83) In the context of pancreatic cancer this could be particularly useful in 
guiding surgical margins during resection and in diagnosis acting as an adjunct or 
substitute for the current practice of analysing a frozen section. Moreover, variations 
in the technology have been developed allowing for diverse application. This includes 
spatially offset Raman spectroscopy (SORS), which allows Raman spectra to be taken 
at a point offset from the point of the laser, allowing for, for example, subcutaneous 
detection.(83) Clinically this provides opportunity for Raman spectroscopy to be used 
as an aid to endoscopic or laparoscopic techniques which could be used in detecting 
changes in an organ that is otherwise anatomically difficult to reach, such as the 
pancreas.  
 
The data collected gives a highly specific chemical fingerprint of the material. In 
biological samples, it is capable of detecting cellular changes.(85) However, the 
Raman signature of some substances can supress other signals. The Raman effect is 
also very weak requiring a highly sensitive instrument and can sometimes be masked 
by background photoluminesence.(85) This can mean that background noise can be a 
problem in analysing samples. Although there are statistical methods of removing 
this background noise, it remains a problem and processing of data once acquired 
can be subjective.  
 
Although Raman is a non-destructive technique, overheating of samples can occur, 
causing the sample to burn, especially with very thin or dry samples. This can often 
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be avoided by reducing the power of the laser, however, this may mean spectra with 
a lower signal to noise ratio (S/N) are acquired.  
 
3.4 Computational Analysis  
3.4.1 Pre-processing  
Pre-processing techniques are necessary to allow analysis of the data by retaining 
pertinent information but removing noise, accounting for sloping baseline effects 
and differences in thickness and concentration of the samples. Steps such as cosmic 
ray removal can be selected in the WiRE software, which uses a combination of 
acquisitions to identify and remove cosmic rays to prevent these influencing the 
spectra.  
 
Baseline correction removes fluorescence from the data. This can be done by a 
number of methods, the most common of which fits a convex polynomial line along 
the baseline of the spectra and removes anything beneath this, thus removing 
background fluorescence.(83) A second differentiation method, where the spectra 
are differentiated twice, can also be used, however this can cause the spectrum to 
lose its shape and can then only be normalised by vector normalisation.(83) 
 
Normalisation techniques are usually subsequently employed to account for 
differences due to thickness or concentration of the sample. Two commonly used 
techniques are min-max normalisation or vector normalisation. Min-max 
normalisation requires a consistent, stable peak in all of the spectra,(83) often 
phenylalanine, Amide I or Amide III. For this method, the highest intensity of the 
chosen peak is converted to 1 and the intensity of a nearby peak, with minimal 
intensity, converted to 0. All other peaks are then scaled accordingly. Vector 
normalisation does not rely on a single peak, instead dividing the entire spectrum by 




SID:32164444  Hawwa A. Bham 
 54 
3.4.2 Processing  
3.4.2.1 Multivariate Analysis 
An analysis is described as multivariate when looking at the joint behaviour of 
multiple independent variables, as opposed to univariate analysis, where there is a 
single dependent variable. In spectroscopy, this is useful as each wavelength, of 
which there are hundreds, is an independent variable.   
3.4.2.2 Principle component analysis  
Principle component analysis (PCA) is a multivariate technique commonly used in 
vibrational spectroscopy to identify variation in the data. It is able to transform a 
large number of variables, wavenumbers in the example of spectroscopy, to a 
smaller number of uncorrelated variables.(87) In spectroscopy, there often hundreds 
of wavenumbers, making it impossible to visualise all of the data and identify subtle 
differences. PCA minimises data by producing linear combinations of the variables 
and ranking them based on variance.(87) Thus, a large data set is converted to a 
smaller one, still containing most of the variance in the data. The first 3 principle 
components are frequently used as they contain up to 99% of variance in the 
data.(83)  
 
Principle components are visualised with each spectrum converted to a point on a 
scores plot and principle components as the axis of the plot. The further apart these 
points on the scores plot, the greater the spectral and therefore biochemical 
difference.(83) Principle component 1 is the line of greatest variance within this 
data.(87) Subsequent principle components are orthogonal to each other, each 
displaying succeeding degrees of variance, independent from one another.(83) As 
principle components are eigenvectors, with the correspondent eigenvalues as PCA 
factors, of the original covariance matrix of the data, PCA allows us to understand 
the data from an angle of greatest variance, without changing the data.(87) A greater 
PCA factor suggests greater variance in the data, and so greater biochemical 
difference.(83) However, as an unsupervised technique it is not given information 
about categories in the data and so PCA is unable to distinguish intracategory 
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variance from intercategory variance, unless this is the greatest natural variance in 
the data.(83, 87) This can be a limitation with biological samples as there is often 
significant biochemical difference within categories.(83) However, where variance is 
found, its detection is unbiased as the technique is unsupervised. 
 
The data can also be viewed as loadings curves, showing the contribution of each 
wavenumber to the variance for a given principle component. In this plot the 
wavenumbers are viewed on the X axis and variance coefficient on the Y axis; 
wavenumbers with a greater variance between spectra have a greater coefficient 
and so a larger peak.(83) This peak can be either positive or negative and both are of 
equal value where the magnitude of the peak is the same. As loadings plots can 
distinguish important wavenumbers which create greatest variance in the data, this 
can then be worked backwards to identify the corresponding biochemical and so be 
helpful in identifying potential novel biomarkers.  
3.4.2.3 Principle Component Analysis – Linear Discriminant Analysis (PCA-
LDA)  
Linear discriminant analysis (LDA) is a supervised technique, which draws out 
differences in the data dependent on pre-categorised classes.(88) It holds the 
advantage of being able to prioritise variation between classes over variation within 
classes, although this can mean that LDA analysis can ‘overfit’ the data and impose a 
bias when processing, dependent on preconceived classification of the data.(83, 88)  
 
Following LDA transformation, the Euclidean distance within the LDA transformed 
space is equivalent to the Mahalanobis distance between any point and the centre of 
the class.(83) Hence, the Mahalanobis distance and LDA transformation can both 
account for the ellipsoidal clustering of the data.(83, 89) LDA can be particularly 
useful in that, with enough spectra and samples, sensitivity and specificity values for 
the contribution of wavenumbers to the variation in the data can be calculated.(90) 
This is particularly helpful with a view to clinical application as these values are 
needed for translation to clinical practice, to allow patients and practitioners to be 
adequately informed when such information is being used to aid diagnosis. However, 
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at a research stage, utilising LDA analysis is dependent on having enough samples 
and spectra to carry out this method of processing, which can be difficult with rare 
diseases.(89)  
 
PCA-LDA is the application of LDA analysis on factors derived from an initial PCA of 
the data.(83) It has the advantage of requiring a smaller data set than LDA. In this 
case using 10 PCA factors provides enough information to give an adequate analysis 
of the data, without so much information that LDA overfitting occurs or information 
coming from background noise obscures the interpretation of loadings plots.(83) 
 
3.5 Use of Raman Spectroscopy in Pancreatic Cancer Research  
While Raman spectroscopy has been widely used in the detection of a number of 
cancers, including breast, skin and gynaecological cancers amongst others, as well as 
in cancer surgery guidance, suggesting potential for its use, very little research has 
been done on the potential use of Raman spectroscopy in pancreatic cancer.(84, 91)  
 
Much of the current literature has focussed on developing detection markers, 
utilising SERS to identify and detect known and emerging biomarkers, thereby 
improving the detection limits of these proteins which are found in low quantities in 
serum.(28, 92-94)  
 
The MUC4 and CA19-9 biomarkers have previously been detected, using a SERS 
based sandwich immunoassay, with a limit of detection of 1ng/ml and 27ng/ml 
respectively.(94) More recently a SERS based immunoassay has been developed 
using gold nanoparticles, to detect CA19-9, MUC4 and MMP7 in serum, with the 
potential to detect under 2ng/ml-1 concentration of each of the biomarkers and 
ability to detect the biomarkers simultaneously.(28) The authors conclude that such 
a sensitivity should be sufficient to detect these biomarkers and differentiate 
between normal and diseased patients, particularly using simultaneous detection of 
all 3 biomarkers.(28) These studies have shown potential use of Raman spectroscopy 
and in particular SERS, where more conventional methods such as enzyme-linked 
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immunosorbent assay and radio immunoassay have failed to provide adequate 
sensitivity in detecting and utilising new biomarkers.   
 
The development of the potential use of SERS aims to provide a solution to the lack 
of detection limits of current clinical blood assays. It has been suggested that, at 
present, biomarkers being shed by a developing tumour burden could be 
undetectable in blood samples for more than 10 years(93).  Therefore, use and 
development of SERS based immunoassays is currently a popular area of research 
with a number of recent developments, focussing on improving the performance of 
nanoparticles to identify ways by which the sensitivity can be improved and the 
Raman signal stabilised, to provide reproducible and easily interpreted results.(28, 
93, 95) The use of multiplex detection for pancreatic cancer, to improve specificity as 
well as sensitivity of biomarkers has been of particular focus, to provide a solution to 
the significant problem of lack of specificity of CA19-9.(28, 92) There is general 
agreement in the literature that SERS is able to provide at least similar degree of 
accuracy to ELISA, but has the advantage of needing a smaller sample size and a 
lower limit of detection.(92-94)  
 
Raman spectroscopy has also been shown to be able to differentiate between 
healthy pancreatic b cells and insulinoma cells in rat model.(95) There is therefore 
the potential for a similar methodology to be extrapolated to differentiate between 
pancreatic cancer in the exocrine pancreas and normal pancreatic tissue and so 
identify differences which could aid with the diagnosis and surgical resection of 
pancreatic cancer.  
 
Another study on a mouse model, attempted to use injected surface enhanced 
resonance Raman spectroscopy (SERRS) nanostars to detect tumour margins at 
resections.(96) This found multiple sub-millimetre foci could be identified using a 
Raman spectral fingerprint of SERRS, where no residual tumour was seen with white 
light imaging.(96) Histological examination demonstrated that SERRS nanostars 
accumulated in the tumour stroma and within epithelial tumour cells and were also 
found in and able to identify PanIN lesions.(96) Importantly this method showed high 
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specificity for malignant regions as the SERRS nanostar is non-existent in biological 
tissue and so the Raman signal can only be detected in malignant tissue, where there 
has been uptake of the reporter molecule.(96)  However, the mechanism by which 
SERRS-nanostars are taken up by malignant tissue is unknown, although it is 
hypothesised that macropincytosis could be the underlying mechanism, caused by 
malignant mutation.(96)  This mechanism could however, vary been between 
different mouse models and human patients and so the specificity of the method 
could also vary. Therefore the work with injected SERRS nanostars would require 
significant further work for translation to humans.   
 
While the use of Raman spectroscopy in pancreatic cancer is beginning to show 
potential, this is a very new area of research, with very little literature. Notably, 
Raman spectroscopy on human pancreas tissue is not described in the current 
literature nor is there any work differentiating healthy pancreas from malignancy of 
the exocrine pancreas using Raman spectroscopy, which are significant limitations to 
the potential translation of the technique to clinical practice. 
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3.6 ELISA  
Enzyme-linked immunosorbent assay is a plate-based technique used to detect and 
quantify peptides, protein, antibodies and hormones. The technique is dependent on 
an immobilised antigen and highly specific antibody-antigen interaction with the 
antibody linked to an enzyme. Assessing the enzyme activity, by incubating with a 
substrate, allows for detection and quantification of the antigen.(97)   
 
The antigen of interest needs to be immobilised to a solid surface, either directly 
adsorbed to the assay plate or by using a capture antibody that is attached to the 
plate. Detection can be direct, the antigen is linked to a primary antibody linked to 
an enzyme, or an indirect method, where the primary antibody is linked to a 
secondary antibody.  
 
The most common and sensitive method is a ‘sandwich’ assay, which captures the 
antigen between two primary antibodies.(98) An antibody is attached to th plate, to 
which the antigen is linked and second primary antibody attaches to the antigen. A 
secondary antibody is linked to the primary detection antibody and this links to the 
enzyme, the activity of which is measured to allow for detection. As the primary 
antibody has several epitopes to which the secondary antibody can bind, the signal 
can be amplified, increasing sensitivity.(97) In this method, it is important that the 
secondary antibody is specific to the primary detection antibody and not the capture 
antibody to ensure the assay is specific to the antigen. This is often achieved by using 
a capture antibody from a different species to the detection antibody.  
 
While the direct detection method is often faster and eliminates any potential 
affinity between the detection antibody and capture antibody, ensuring good 
specificity to the antigen, it is less sensitive as the signal cannot be amplified.  
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3.7 Immunohistochemistry  
Immunocytochemical techniques are techniques developed over the past 60 years, 
which utilise antibodies to give information where the morphology and clinical data 
alone cannot confirm a diagnosis. In the context of cancer, these techniques are 
particularly useful as antibodies which bind to cytokeratin, the epithelial 
cytoskeleton, are specific to the diagnosis of most cancers.(99)   
 
While immunofluorescence staining enables the visualisation of such antigens, it has 
the disadvantages of needing a fluorescence microscope and limited detail of the 
morphology of labelled cells. Immunohistochemical techniques overcome this by 
counter staining with haematoxylin. In addition, samples prepared for 
immunohistochemical staining can be stored for longer periods of time as unlike the 
fluorescence dyes, the staining intensity does not diminish with time.(99)  
 
For samples fixed in formalin and paraffin, which enable the samples to be sectioned, 
many epitopes are masked or destroyed during the fixing and processing steps.(99) 
Hence, it is necessary to first retrieve antigens from the samples before staining. This 
can be done using a number of methods including, proteolytic enzyme digestion, 
microwave antigen retrieval, pressure cooker antigen retrieval and steam.(99) Of 
these, microwave antigen retrieval is the most suited to a laboratory, both because 
of speed and safety.  
 
A number of methods for immunohistochemical staining have been developed. 
These can be split into a direct or indirect method. The direct method uses a primary 
antibody directly conjugated to a label. While this is a simpler method, requiring a 
single application of antibody it has a lower sensitivity than the indirect method.(99) 
The indirect method requires the application of a primary antibody, followed by a 
secondary labelled antibody directed against the first. Horseradish peroxidase is the 
most commonly used label for this method, with an appropriate chromogen 
substrate.(99)  
 
SID:32164444  Hawwa A. Bham 
 61 
Hypothesis  
It is hypothesised that Raman spectroscopy is able to differentiate between healthy 
and cancerous tissue in the exocrine pancreas. It is thought that these differences 
will be seen in peaks related to DNA and protein which will identify and provide 
further information about genotypic and phenotypic changes to the cells involved in 
the development of pancreatic cancer. These changes are expected to be identified 
in a way that enables the potential use and translation of the technology into clinical 
practice.  It is further hypothesised that the matricellular protein SPARC plays a role 
in the development of pancreatic cancer and its production by PSCs is dependent on 
the interaction between cancer cells and PSCs.  
Aim  
This study aims to identify the differences between cancerous and healthy pancreatic 
tumour resection tissue using Raman spectroscopy. It aims to utilise Raman 
spectroscopy to analyse the patients’ blood and resections to identify potential novel 
biomarkers which could be used in the screening, diagnosis and detection of tumour 
margins in pancreatic cancer.  
 
A primary objective is to use cocultures of HPAF-II and PSCs, aiming to understand 
the interactions between these cell types and their role in both the production of 
SPARC and development of pancreatic cancer. This is hoped to be achieved by using 
ELISA and Raman spectroscopy to provide information and analyse the interactions 
between cells.  This ultimately aims to create a 2D cell line model, which is able to be 
characterised using Raman spectroscopy, which could be used in further research.  
 
Overall, this study aims to demonstrate the potential utility of Raman spectroscopy 
in identifying the development of pancreatic cancer and differences between healthy 
and cancerous pancreatic tissue and providing information as to why these changes 
may occur. It aims to be able provide a basis for further research allowing translation 
of the technology to clinical practice. 
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Chapter 4 – Methods and Materials  
4.1 Sample Preparation  
4.1.1 Human Tissue  
Tissue from human pancreatic cancer tumour resections were taken, with ethical 
approval from Greece (St Savvas Cancer Hospital and Red Cross Hospital in Athens) 
and the UK (REC approval: 17/YH/0283), after surgery from patients diagnosed with 
PDAC (Table 2). The tissue was frozen at -80°C for transportation and storage. It was 
defrosted, cut and placed fresh on calcium fluoride (CaF2) slides to be scanned using 
the Raman spectrometer. Samples with a gross tissue margin were cut in line with 
the margin, giving a sample with healthy tissue, a tissue margin and cancerous tissue 
(Figure 2).  
 
Once scanned fresh, the samples were fixed and stored in 10% neutral buffered 
formalin and scanned again, using the same settings, to identify any differences in 
spectra between fresh and fixed tissue. Formalin fixation was used as it causes less 
protein degradation and tissue shrinkage than fixing using ethanol.(100) 
 
4.1.2 Preparation of Blood samples for Raman spectroscopy and SERS  
Blood samples from each patient were also received frozen, for patients 1, 2 and 3, 
and stored at -80°C. The blood sample from patient 1 was received as serum and 
samples from patients 2 and 3 were received as whole blood. Samples were 
transferred to a quartz well plate for scanning. For SERS measurements blood was 
mixed with an equal volume of 60nm gold nanoparticles (BBI Solutions, UK), and 
incubated at 4°C for 2 hours.(101, 102) The gold nanoparticles were citrate capped, 
suspended in water with no preservative at a concentration of 2.6x1010 per ml.  
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a)   
b)  
Figure 2: a) resection patient 2, dashed line shows where tissue was cut before spectra 
were taken, b) resection patient 3, arrow indicates direction of spectral acquisition 
 
Arrow indicates 
direction of spectral 
acquisition   
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Pancreatic tumour resections – Patient Characteristics    
 








1 M 75 Head/uncinate  Undifferentiated 
(anaplastic or 
sarcomatoid) carcinoma  
 Stage IIA: T3, N0, M0 
 
Incomplete Y N 
2 F 60 Head/uncinate Undifferentiated 
carcinoma with 
osteoclast-like giant cells 
Moderate Stage IIA: T3, N0, M0 Complete Y Y 
3 M 73 Body/neck Ductal Adenocarcinoma  Moderate Stage IIA: T3, N0, M0 Incomplete Y Y 
4 M 73 Head  Ductal Adenocarcinoma  Moderate Stage IIB: T2, N1, M0 Complete N N 
 
Table 2:Patient characteristics for study samples 
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4.1.3 Cell Lines 
A human pancreatic cancer cell line, HPAF-II (ATCC, LGC standards, UK), and human 
pancreatic stellate cells (PSC) (iXCell Biotechnologies, San Diego, CA, USA) were 
initially cultured in Dulbecco’s modified eagles culture medium, supplemented with 
10% foetal bovine serum (FBS), 1% penicillin and 1% streptomycin. Confluent cells 
were split by removing media and washing with 5ml of phosphate buffer solution, 
before adding 5ml trypsin, both warmed to 37°C and incubating for 5 to 10 min at 
37°C and 5% CO2, to allow the cells to detach. The trypsin was then neutralised with 
5ml of media and then centrifuged at 400rpm for 5 min. The supernatant was 
removed and the cells suspended in 15ml of media in a 75mm2 flask to allow to grow.  
 
Experiments were conducted with confluent cells, ensuring all cells were at the same 
stage in the cell cycle, allowing for comparable results. For Raman experiments the 
cells were transferred to CaF2 slides in petri dishes and allowed to grow. HPAF-II cells 
were grown on CaF2 slides for varying lengths of time to identify a timepoint which 
would mean cells were suitably attached to the slide to be able to acquire spectra. 
The optimal method was to deposit cells on the slide and incubate at 37°C and 5% 
CO2 for a minimum of 3 hours, allowing cells to rest and attach for before adding 
10ml warmed media to the petri dish, to ensure cells were attached to the CaF2 slides 
and did not wash into the petri dish. Cells were then allowed to grow for 7 days, 
which enabled enough growth and attachment for spectral acquisition.  
4.1.3.1 Coculture 
For co-culture experiments, HPAF-II cancer cell line was grown with and without 
human pancreatic stellate cells to identify if a model for tumour stroma could be 
produced for future research. The cell line was initially grown alone for tests, then 
alongside combinations with fibroblasts at ratios of 1:1, 1:3 and 3:1 (cell line:PSC). 
Ratios were calculated based on number of cells and each combination had Raman 
spectra acquired from live cells, after being allowed to grow for 7 days. Cells were 
counted after centrifuging, by resuspending the pellet in 1ml media and depositing 
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0.1ml onto a haemocytometer for counting. The average figure was then multiplied 
by 10,000 to estimate the number of cells in 1ml.  
 
Cells were co-cultured both on a slide, where they could directly interact, and in an 
insert in a wells plate, where cells types grew without direct contact with one 
another but sharing media, and therefore growth factors and other secreted 
products. Media was changed to media without FBS at day 5, to allow this media to 
be conditioned before ELISA testing.(103) This growth medium, in each case, was 
tested to identify SPARC production and secretion using quantitative ELISA.  
4.1.3.2 Preparation of Cells for SERS measurements 
Surface enhanced Raman spectroscopy (SERS) was subsequently employed on fresh 
cells, using 60nm gold particles (BBI Solutions, UK), to enhance any signal that may 
have been specific to a potential biomarker. The gold nanoparticles were citrate 
capped, suspended in water with no preservative at a concentration of 2.6x1010 per 
ml. Cells were grown in co-culture using the same method previously described and 
were incubated with the SERS substrate at a volume ratio of 2:1 
(media:nanoparticles) for 7 days at 37°c and 5% CO2, before scanning with the Raman 
microspectrometer.(86)  
 
4.2 Raman Spectroscopy  
4.2.1 Calibration  
An inVia Raman microspectrometer (Renishaw plc, Gloucestershire, UK) with a 
785nm laser was used to acquire spectra from the samples. The instrument was 
initially allowed to stabilise for 30 minutes after being switched on, to ensure 
constancy of the laser and charged coupled device. The instrument was calibrated 
daily, first ensuring the laser was correctly aligned and in focus. Secondly, a 
measurement taken of silicon, with an expected peak at 520.5cm-1 and the absolute 
intensity of this peak was recorded. Calibration was needed daily to ensure the laser 
began at the same starting point before taking measurements, ensuring 
measurements were accurate and comparable. Silicon was used for this purpose as it 
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has a very clear single peak at 520.5cm-1. Where the peak had shifted the instrument 
was optimised to ensure a measurement at 520.5cm-1. A further calibration 
measurement was taken using polystyrene, as this has peaks in the biochemical 
fingerprint. The intensity of the two largest peaks, wavelengths 1001 cm-1 and 1031 
cm-1, was recorded with the intensity of the 1001 cm-1 peak expected to be four 
times that of the peak at 1031 cm-1. 
 
4.2.2 Optimisation  
Optimisation of Raman setting was needed to identify a power setting which would 
give maximal Raman signal without damaging the sample and a time and acquisition 
setting which was both time effective and gave good signal to noise ratio, allowing 
identification of important peaks.  Initial optimisation was done using a sample of 
HPAF-II cells grown for 24 hours on calcium fluoride (CaF2) slides, as these have no 
Raman signal, and bought into focus under the microscope. A range of 593cm-1 to 
1705cm-1 was selected as this range includes peaks in the biological spectrum. 
Spectra were then taken to identify the most appropriate power of the laser, which 
would not cause damage to the samples.  
 
Figure 3:Optimisation of laser power settings for Raman spectroscopy. A final setting of 
100% was chosen as this gave maximal Raman signal and did not damage the samples. 
Initially spectra were taken with the laser varying in power, to identify the maximal 
power that could be used without causing damage to samples as this would give the 
maximal Raman signal and information. The optimal laser power was  100%; this gave 
the greatest intensity of the laser and did not damage the samples (Figure 3). 





Figure 4:Graphs showing rationale for optimisation of settings a) overall optimisation of 
settings, b)optimisation of time setting using 1 acquisition, c) optimisation of combined 
time and acquisition setting 
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The combination of time the laser focussed on the sample and the number of 
acquisitions was tested next to identify a setting giving a spectrum with the optimum 
signal to noise ratio, allowing identification of biological peaks (Figure 5a). 
To do this, spectra were initially taken at differing time settings, using only 1 
acquisition (Figure 5b). Spectra were then taken combining time with numbers of 
acquisitions, to identify which combination both gave the optimal signal to noise 
ratio and so allowed for the best identification of potential peaks in the spectra and 
was most time effective (Figure 5c). A final setting of 15s by 4acc was used to take 
measurements.  
 
4.3 Spectral Acquisition 
4.3.1 Tissue  
Spectra were taken using a 785nm laser and  x50 long working distance objective. 
Settings for scanning with the Raman spectrometer were optimised. (Figure 5) A final 
setting used laser power of 100% and 15s and 4 acquisitions; these were the same 
settings as used for cell lines, making spectra comparable to cell line spectra. Spectra 
were taken in a line, with a minimum distance of 250µm between spectra, to ensure 
independent measurements (Figure 2). Spectra were taken either moving from tissue 
which appeared healthy to that which appeared cancerous or vice versa, to ensure 
results were due to changes in the samples and not degradation of the laser over the 
course of the day. The number of spectra taken varied dependent on the length of 
the resection, with a minimum of 15 spectra acquired per sample.  
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Figure 5:Graph showing spectra for optimisation of time and acquisition setting for tumour 
resections. Spectra taken from patient 1 tumour sample. Final settings were optimised to 
15s by 4 acquisitions.  
 
4.3.2 Blood  
Blood samples were transferred to a quartz well plate for scanning. Spectra were 
taken, using a 785nm laser and x15 long working distance objective, from both fresh 
blood as well as SERS measurements to enhance signal.   
 
The depth at which the measurement was taken was optimised for each sample. The 
rationale for depth optimisation is demonstrated, using spectra from patient 1’s 
blood sample, in Figure 6. The same method was used for all blood samples. The 
depth was optimised by initially setting the z axis to 0 at the top of the wells plate 
and then taking a single 10s measurement every 400µm beginning from the bottom 
of the wells plate, to the top (Figure 6a). A second depth optimisation measurement 
was taken, with spectra taken every 100µm in the region identified as the optimum 
based on the initial measurements (Figure 6b). This gave the optimum depth from 
which to acquire spectra. Raman settings were optimised to 15s by 40 acquisitions 
(Figure 7) and SERS settings to 60s by 3 acquisitions (Figure 8). A laser power of 100% 
was used as the sample was liquid and so could not be damaged, by this laser. 
 




Figure 6:Spectra demonstrating rationale and method of depth optimisation using patient 
1’s blood sample a) first depth optimisation with spectra taken every 400µm moving down 
from the top of the well plate, the spectrum at -3700µm on the z axis can be seen as the 
clearest spectrum for this sample b) second depth optimisation with spectra taken every 
100µm from -3000 to -4000µm. The clearest spectrum was seen at -3900µm and all other 
spectra were taken from this point for this sample. 





Figure 7:Graphs showing spectra for optimisation of time and acquisition setting for 
tumour resections. Spectra taken from patient 1 blood sample, a)optimisation of time 
settings with using 1 acquisition b)optimisation of time and acquisition settings, c) raw 
spectrum for final setting of 15s by 40 acquisitions 
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Figure 8:Graph showing spectra for the optimisation of settings for blood samples with 
SERS. Final settings were optimised to 60s by 3 acquisitions  
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4.3.3 Cell Lines  
Spectra were taken using an x60 immersion objective to acquire spectra, with cells 
still in media.(85) Spectral acquisition was limited to 1 hour after cells were removed 
from the incubator to ensure spectra were taken from live cells. The settings for 
acquiring spectra were optimised using the described method. The spectra were 
taken at a laser power of 100%, using a setting of 15s and 4 acquisitions (Figure 4). 15 
independent spectra were taken per sample.  
 
Cells were then fixed in 10% neutral buffered formalin for 30 minutes and scanned 
again however this gave a noisy spectrum and with no identifiable peaks. Fixed cells 
were stored in 10% neutral buffered formalin at 4°C before immunohistochemistry, 
to identify SPARC, was attempted on the fixed cells.  
4.3.3.1 SERS on Cells   
Surface enhanced Raman spectroscopy (SERS) was subsequently employed on fresh 
cells, using 60nm gold particles (BBI Solutions, UK), to enhance any signal that may 
have been specific to a potential biomarker. The gold nanoparticles were citrate 
capped, suspended in water with no preservative at a concentration of 2.6x1010 per 
ml.  Cells were grown in co-culture using the same method previously described and 
were incubated with the SERS substrate at a volume ratio of 2:1 
(media:nanoparticles) for 7 days at 37°C and 5% CO2, before scanning with the Raman 
microspectrometer.(86) SERS settings were optimised to 100% power, using a setting 
of 1s by 3 acquisitions, to allow cosmic ray removal (Figure 9a). Spectra were taken 
using a mapping setting, as there were significant differences between different 
areas of cell and due to the distribution of nanoparticles (Figure 9b). Approximately 
200 spectra were taken from 2 locations on every slide, giving a total of 
approximately 400 spectra per slide.  




Figure 9:Graph showing spectra for the optimisation of settings for cell cocultures with 
SERS. a) Optimisation of power setting for cells with AuNP. 100% power was suitable and 
did not damage the samples. b) Optimisation of time and acquisition settings. 1s and 1 
acquisition gives a clear spectrum but the quality and configuration of spectra vary 
dependent on the location from which they are taken. 
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4.4. Raman Data Analysis  
4.4.1 Pre-processing  
Data was analysed using an in-house written Matlab (The Mathworks Inc, MA, USA) 
script.(104) All spectra were baseline corrected using a polynomial order of 6, to 
remove fluorescence. This polynomial order was chosen to sufficiently remove 
background noise and fluorescence with minimal loss of Raman signal intensity and 
change to the configuration of the peaks (Figure 10). Vector normalisation and min-
max normalisation using both the phenylalanine and amide III peaks were then 
tested on the baseline corrected data. Vector normalisation was chosen as the 
normalisation technique for the data as this gave a representation of the chemical 
peaks after scaling for volume, allowing for comparison, as differences caused by 
focussing depth and thickness across the samples were removed. While both vector 
and min-max normalisation were suitable techniques for achieving this, vector 
normalisation caused minimal change to the original data (Figure 11).  All data was 
pre-processed using the same settings to allow spectra to be comparable. 
 
a) b)  
c) d)  
Figure 10:Baseline corrected data, a) polynomial order 4, b) polynomial order 5, c) 
polynomial order 6, d)polynomial order 7 
 





Figure 11:a) Resection data baseline corrected, polynomial order 6, vector normalised; 
Class 0&1 – patient 1 fresh and fixed, Class 2&3  – patient 2 fresh and fixed, Class 4&5 – 
patient 3 fresh and fixed, Class 6&7 – patient 4 fresh and fixed b) Mean spectrum of all 
resection data baseline corrected, min-max normalised to phenylalanine peak, c) Mean 
spectrum of all resection data baseline corrected, min-max normalised to amide III peak 
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4.4.2 Processing  
Data was processed using PCA and PCA-LDA analysis, using an inhouse Matlab script, 
which calculated 10 PCs before scores and loadings plots were reviewed. For 
resection data, an initial PCA-LDA scores plot was done to determine whether it was 
possible to separate data based on if they were acquired from fresh or fixed tissue. 
LDA alone was not used as there were not enough spectra within each class to ensure 
the analysis would not overfit the data.  
 
Maps acquired from cells using SERS were reviewed and shaded using signal to 
baseline analysis for wavenumbers 600-800cm and 1325-1345cm, which are both 
regions which identify changes to DNA. The data was pre-processed in WiRE 4.2 using 
mean centring and vector normalisation, to keep pre-processing steps as similar as 
possible to that of the cell data without SERS. An intensity range of 5-95% was 
selected to give clearer visual representation of the location of the  SERS peaks as 
spectra with the lowest intensity, which were unlikely to be SERS spectra and those 
with the highest intensity where the receiver had been saturated was minimalised in 
the shading, They were also shaded by PCA, using the full range of intensity and 




Quantitative ELISA for SPARC was done on media from cells co-cultured both in  
direct contact and in indirect contact, using an insert in a wells plate. A human SPARC 
ELISA kit (Abcam, Cambridge, UK) was used and relevant company protocol followed. 
Briefly, samples of conditioned FBS free media from cocultures and serum from 
patient 1 were defrosted to room temperature and prepared by centrifuging, to 
remove any remaining cell matter. Standards were then prepared to allow for 
comparison of concentrations. Samples and standards were distributed to 
appropriate wells and an antibody cocktail added. This was followed by a 1 hour 
incubation period at room temperature on a plate shaker. Each well was washed 3 
times with a wash buffer, before a tetramethylbenzidine (TMB) substrate was added 
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and samples incubated for 10 minutes. A stop solution was then added and the plate 
was read at 450nm.  
 
4.6 Histology 
A protocol for immunohistochemical staining developed from Bancroft’s Theory and 
Practice of Histological Techniques was used to prepare and stain both slides of 
cocultured fixed cells and fixed tissue resections.(99)  
 
Formalin fixed tissue samples were embedded in wax, by transferring from formalin 
to ethanol (70% then 90%) to xylene and incubating for 30 minutes at each stage, 
before embedding in paraffin. Samples were embedded by incubating for 30 minutes 
in hot paraffin wax twice, to allow the wax to permeate the samples before moving 
to a wax block. Embedded samples were sliced as a cross-section to 4µm using a 
microtome and dried overnight before staining. 
 
4.6.1 Haematoxylin and Eosin staining  
Paraffin embedded tissue sections were transferred through xylene to ethanol 
(absolute and 90%) to water, standing for 5 minutes at each stage, to allow for 
staining with water based dyes. They were then stained with Harris Haematoxylin, 
followed by Eosin Y, washing for 5 minutes under running tap water after the 
application of each dye to allow the stain to develop. They were then transferred 
back through ethanol to xylene before being mounted using a xylene based mounting 
agent.  
 
4.6.2 Immunohistochemical staining  
The samples were initially prepared by deparaffinising and endogenous peroxidase 
activity was blocked by incubating in 0.5% hydrogen peroxide in methanol for 10 
minutes. Samples were then rehydrated and washed before transferring to tris 
buffered solution (TBS). The microwave antigen retrieval method was used, heating 
samples placed in a citrate buffer for 10 minutes in a 750W microwave at full power.  
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The samples were stained using horseradish peroxidase (HRP) as a conjugate. Slides 
were washed in TBS plus 0.025% TritonX-100 for 5 minutes, twice, with gentle 
agitation. Antigens were blocked with 1% Bovine serum albumin (BSA) in TBS 
incubating at room temperature for 2 hours, before adding the SPARC mouse 
monoclonal IgG2B primary antibody (Santa Cruz biotechnology, Texas USA, SC:398419, 
Lot #A2618) diluted 1:50 in TBS with 1% BSA. After incubating overnight at 4°C slides 
were rinsed twice in TBS plus 0.025% Triton X-100  for 5 minutes with gentle 
agitation. They were then incubated in 0.3% hydrogen peroxide in TBS for 15 
minutes, before the IgG-HRP-conjugated goat anti-mouse secondary antibody (Santa 
Cruz biotechnology, Texas USA, SC: 2031, Lot #G1715), diluted 1 in 500 in TBS with 
1% BSA, was added to the slide and incubated at room temperature for 1 hour. 
 
The stain was developed with diaminobenzidine (DAB) for 10 minutes at room 
temperature. 
 
SID:32164444  Hawwa A. Bham 
 81 
Chapter 5 – Results and Discussion - Resections and Blood  
Pancreatic cancer presents an increasing mortality burden, arising from late diagnosis 
and a high rate of recurrence of disease.(1) An insidious onset of non-specific 
symptoms as well as the invasive nature of current diagnostic methods means many 
patients present late, with a cancer which is non-resectable.(1) Current diagnostic 
and pathological methods also show limited in accuracy in the detection and 
diagnosis of pancreatic cancer.(105)  While surgical resection can be curative, even 
after resection many cancers recur, potentially because the tumour margin is difficult 
to identify.(1, 37, 38) This presents the need for the application of a new method 
which is both able to differentiate healthy and cancerous tissue more accurately and 
could be used in a clinical setting.  
 
Raman spectroscopy has been shown to be able to identify a number of cancers, 
although its application to pancreatic cancer is very limited.(91) The current literature 
differentiating healthy pancreas from that which is diseased, using Raman 
spectroscopy, does so using animal models and there is no literature showing 
differences between healthy and cancerous tissue in the exocrine pancreas.(95, 96)  
 
This chapter displays the results of the use of Raman spectroscopy on human tissue 
resections, to identify differences between healthy and cancerous tissue. It further 
shows the results of Raman spectroscopy on blood samples from patients with 
pancreatic cancer and the differences identified in these samples. These results aim 
to demonstrate the utility of Raman spectroscopy to analyse both fresh and fixed 
human pancreatic tissue, in a way which, with further research, could be used in the 
screening, diagnosis and detection of tumour margins in pancreatic cancer. 
 
In line with the hypothesis for this study, these results show Raman spectroscopy is 
able to differentiate healthy and cancerous human tissue in the exocrine pancreas as 
well as identify variation between blood samples from patients with different types 
of pancreatic cancer. This provides the basis for further research which could 
promote the application of Raman spectroscopy to clinical practice. 




Figure 12:Spectra for resections from all patients classed by methods of sample preparation 
(fresh and fixed) and cancer status (cancer, healthy, unknown) a) Raw spectra b) Baseline 
corrected spectra (polynomial order 6) 
 
Figure 13: Vector normalised average spectra (polynomial order 6) data for resections from 
all patients classed as by method of sample preparation (fresh and fixed) and cancer status 
(cancer, healthy, unknown). The peak at 1662cm-1 is visibly higher in fresh cancerous tissue, 
than in healthy or unknown tissue. Arrow shows collagen peaks which is higher in fixed 
cancerous tissue than healthy or unknown tissue.  
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Initial observation of spectra suggests a significant difference in fluorescence 
between cancerous and non-cancerous tissue, with fresh tissue less fluorescent than 
fixed tissue, and the greatest fluorescence seen in the tumour margin and normal 
tissue (Figure 12a).  This is to some degree surprising as cancer tissue contains 
collagen I, which is naturally fluorescent, whereas the data shows normal tissue to be 
more fluorescent than the cancer tissue. Although this is not a result of the Raman 
signal and can be removed though baseline correction, the very clear differences in 
fluorescence suggest that fluorescence may also be a useful way of differentiating 
cancer from normal tissue.  
 
After both baseline correction and vector normalising there are still visible 
differences in the peaks between classes, suggesting Raman may also give important 
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5.1 Cancer Differences 
a)  
b)  
Figure 14:PCA of all resection spectra, classed by visible presence of cancer a) PCA loadings 
plot for all resections, b) PCA scores plot for all resections 
 
Along PC1 there is a cluster of cancer spectra, suggesting PCA is able to differentiate 
based on malignancy of tissue, regardless of whether tissue is fixed (Figure 14b). It is 
worth noting that there was variation in cancer types between patients, both in the 
location of the tumour and histological cancer type, which may account for some of 
the heterogeneity in cancer and normal tissue classes. There is separation between 
fresh and fixed tissue along PC3, showing variation, as expected, in the collagen 
region of peaks (Figure 14). After separating fresh and fixed tissue, and classing by the 
presence of cancer, differences between cancerous and normal tissue were clearer. It 
is also difficult to attribute peaks and causes of variation to the presence of cancer or 
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to the method of sample preparation without first identifying the impact of fixing the 
tissue.  




Figure 15:PCA-LDA showing differences between fresh and fixed tissue a) PCA-LDA 
loadings plot, b) PCA-LDA Scatter plot, fresh versus fixed tissue, c) PCA-LDA scores plot 
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PCA-LDA analysis shows differences between fresh and fixed tissue (Figure 15). The 
most significant of the differences are in the collagen peaks, with particular changes 
to phenylalanine of collagen (1030cm-1) proline (1044cm-1) C-O or C-N stretching in 
protein (1054cm-1) and skeletal C-C stretching (1060cm-1, 1064cm-1) (Figure 
15a).(106) This is expected as formalin fixes tissue by inducing covalent bonds 
causing cross-linking of proteins,(100) and suggests that the fixing process alters 
these proteins to the greatest degree. As such significant differences can be seen due 
to methods of sample preparation, all further analysis was done with fresh and fixed 
tissue separately.  
 
While clusters of spectra taken from individual patients are well defined and largely 
distinct, there is spread of the data both between classes and within them, 
suggesting Raman spectroscopy can identify differences both between patients and 
within patients. The latter could suggest identification of differences due to cancer 
type or grading, as some samples contained spectra from both healthy tissue and 
cancer tissue.
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5.3 Patient Differences  
a)  
b)  
Figure 16:PCA of fresh tissue; ‘pt’ indicates ‘patient number’  a) PCA loadings plot for fresh 
resection tissue, b) PCA 2D scores plot for fixed tissue, with 95% confidence ellipses. 
 
PCA shows Raman spectra can be used to identify clear variation between patients. 
Confidence intervals (95%) suggest the homogeneity of cancer tissue (Figure 16b); 
patient 1’s sample was only cancer tissue, with no tumour margin in the sample. This 
can also be identified as the spectra for Patient 1 are much more tightly clustered, 
with the smallest confidence ellipse of all samples. Patients 2 and 3  show the 
greatest variation within the patients; these also had the largest grossly visible 
tumour margin of the received samples (Figure 16b), suggesting there is also likely to 
be variation along the tumour margin, due to differences in the tissue type itself.  





Figure 17:PCA of fixed tissue; ‘pt’ indicates ‘patient number’  a) PCA loadings plot for fixed 
resection tissue, b) PCA 3D scores plot for fixed tissue, c) PCA 3D scores plot for fixed tissue 
with 95% confidence ellipses. 
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Interpatient variability can be identified more clearly in fixed tissue than fresh tissue. 
When viewed with 95% confidence ellipses, patients, 1,2 and 4 appear as distinct 
groups, showing PCA analysis to able to clearly differentiate between these patients 
(Figure 17c). There is clear separation between patients 2 and 4 along PC1, and 
between patient 1 and 4 along PC2 (Figure 17b). Patient 3 has greatest overlap with 
other patients; anatomically this was the only body/neck tumour (Figure 17c). The 
greater degree of overlap between patient 3 and 4, compared to the overlap 
between patient 3 and patients 1 and 2, may be a result of both patients 3 and 4 
having ductal adenocarcinomas, whereas patients 1 and 2 had undifferentiated 
tumours.  
 
Patients 1, 2 and 3 also separate most clearly along PC3, showing differences in the 
1028-1062cm-1 range of peaks, attributed to mostly to variations in collagen 
including, collagen content, (1033cm-1) and proline (collagen assignment) as well as 
(1043cm-1), C-O or C-N stretching in proteins (1053cm-1) (Figure 17a).  This may be 
due to the differences in cancer type, or the fact that patient 1’s tissue was only 
cancer tissue, whereas patients 2 and 3 had the greatest amount of healthy tissue 
and tumour margin. There is also less separation between patient 1 and 3, both of 
whom had incomplete resections and so no completely healthy tissue, suggesting 
there is potential for Raman spectroscopy to identify differences between healthy 
and cancerous tissue. Patients 1, 2 and 3 also had different cancer types, which could 
suggest that Raman spectroscopy may also have the potential to differentiate 
between cancer types in pancreatic cancer, as well as between healthy and 
cancerous tissue. However, along PC3 there is greater similarity between spectra 
taken from patient 4 and patient 2 than between patient 3 and 4 (Figure 17b). This is 
despite the fact that both patient 3 and 4 had a ductal adenocarcinoma, whereas 
patient 2 had an undifferentiated carcinoma with osteoclast-like giant cells, 
suggesting the variation along PC3 may be contributing more to the differentiation 
between cancerous and normal tissue than histological type of cancer. The fact that 
spectra from patients 2 and 4 were most similar and these were only 2 patients with 
complete resections adds weight to this theory, as the similarity may be a result of 
the presence of healthy tissue, which was only present in patients 2 and 4.  
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There is also a glycogen (1048cm-1) peak, contributing to PC3, which is surprising as 
the pancreas does not ordinarily store glycogen (Figure 17c). This may therefore be a 
marker of malfunction or a characteristic of the types of malignant cells. 
Alternatively, it may be related to the fact that patients are fasted preoperatively and 
so related to the pancreas’ role in releasing glucagon to convert glycogen to glucose, 
when blood sugar levels are low.  
 
The differences between patients, particularly between patients 2 and 4, based on 
PC1 are due to variations in 1335cm-1 showing differences in the CH3CH2 wagging in  
collagen and nucleic acid and 1341cm-1 showing the presence of an A or G in the DNA 
(Figure 17a).(10) While these differences may be due to differences in the patients 
themselves, as the patients had differing tumour types some of the difference could 
also be attributed to cancer type; it is likely that both factors contribute to some 
degree but it is difficult to assess the degree of contribution of each factor with such 
a small sample. 
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Figure 18:PCA of fresh tissue classed by visible presence of cancer a) PCA loadings plot b) 
PCA 2D scores plot for fresh tissue, Circled – cluster of spectra, separating on PC1 and PC2, 
which could be a class in its own right c) PCA 2D scores plot with 95% confidence ellipses. 
Arrows show 2 spectra from normal tissue which overlap with cancerous tissue.  
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For fresh tissue, there is clear clustering of cancerous and normal tissue, with the 
greatest variation in the tumour margin. Despite the overlap of the 95% confidence 
intervals, there is clear separation of the normal and cancerous tissue, except 2 
spectra (arrows in Figure 18b and 18c). There is also overlap between areas of 
unknown tissue and cancer tissue and similarly between areas of normal and 
unknown tissue, which suggests using Raman enables us to identify where tissue is 
malignant, which cannot be identified by observation of the gross features, by eye, of 
pancreatic cancer alone. Similarly, the 2 spectra from normal tissue which overlap 
with the cancerous tissue could be malignant but without an obviously gross 
appearance of malignancy.  
 
As the classes were separated by eye, based simply on the appearance of cancer 
being whiter and more sclerotic than normal tissue, and the resection samples were 
small, there could be differences in opinion on which areas were definitely cancer and 
which were not, based on operator experience. While histological examination may 
give a more specific inclination of the tumour margin and which areas are cancer and 
normal, there is always some inter-operator variability and opinions are, to some 
degree, subjective. Raman spectroscopy may also be a much faster method of 
achieving a similarly specific classification as it requires minimal sample preparation, 
unlike histological techniques.  The greater degree of variation in the tumour 
margin/unknown tissue, is expected as this area of tissue is likely to be the most 
heterogeneous, with some areas at a more advanced premalignant stage than others.  
 
Along PC1 there is clear separation of cancer and normal tissue with a cluster of 
tumour margin spectra in between (Figure 18b). This suggests that there is separation 
of cancerous and normal tissue due to differences in the proline and COO- bonds 
(Figure 18a). The peak at 1556cm-1 may also suggest some differences in tryptophan 
and various regions of amide II, although these are usually assigned to a peak at 
1554cm-1  or 1558cm-1 (Figure 18a).(107) Similarly, the peak at 1574cm-1  may suggest 
variation due to the presence of guanine or adenine, ordinarily seen at 1573cm-1, or 
ring breathing modes in the DNA bases, previously seen at peak 1575cm-1 (Figure 
18a).(107) The peak at 1662cm-1  is associated with nucleic acid modes, thought to 
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indicate the presence of nucleic acid content in tissues (Figure 18a).(107) The raw 
spectra after pre-processing show a greater intensity of this peak in cancerous tissue 
than in healthy tissue (Figure 13). 
 
However, there also appears to be a cluster on the far left of the graph (circled Figure 
18b) which separates on both PC1 and PC2, which could be a class in its own right. 
The tumour margin spectra, along PC2 could be seen as 2 separate clusters, 
suggesting within the tumour margin there may differences based on premalignant 
changes which can be identified using Raman spectroscopy.  
 
For this cluster (circled in Figure 18b) the separation on PC2 appears to be due 
differences in the phenylalanine peak and peaks associated with changes in the 
collagen and nucleic acid regions (Figure 18a). Changes in the 1325 – 1330cm-1  region 
and at 1335cm-1  and 1343cm-1  are associated with the purine bases of nucleic acids 
and twisting or wagging of CH3CH2 in collagen, with the 1335cm-1  peak more specific 
to the protein assignment of collagen.(107) The peak at 1341cm-1  suggests the 
presence of an A or G of DNA and the peak at 1665cm-1, seen as contributing to the 
variation both along PC1 and PC2, is due to the presence of amide I, often in collagen. 
(107) These differences would be in line with the premalignant changes or indicative 
of a more advanced tumour that could be expected in pancreatic cancer as it is 
known that the cancer stroma contains collagen and malignant changes cause change 
to the protein and DNA structures in cells.   
 
There was minimal separation of fresh tissue along PC3 (PCA scores and loadings 
plots not shown). The loadings plot however, shows variation along PC3 to be based 
on changes in the nucleotide conformation region, 600-800cm-1, of peaks.(107) 
Although this variation is minimal on the scores plot, it may be of great importance as 
identifying changes to the DNA could be imperative in gaining a better understanding 
of the development of PDAC and also identifying the changes in DNA before 
phenotypic changes arise. This could allow for earlier detection and give more 
information about tumour margins during and after surgical resection.  
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The other peaks along PC3, at 596cm-1, 609cm-1  and 614cm-1 suggests the presence 
of phosphatidylinositol, a family of lipids in the class of phosphatidylglycerides, and 
cholesterol.(107) Peaks at 662cm-1 and 665cm-1 suggest C-S stretching mode of 
cysteine in collagen type I and at 700cm-1 the presence of the amino acid methionine, 
(107) which may again be important changes.  Despite there being minimal spread of 
data along PC3, the importance of these peaks could be identified more easily and 
associated more strongly with differences due to cancerous changes or differences 
between patients, with a bigger sample size. 
 
 





Figure 19: PCA of fixed tissue classed by visible presence of cancer a) PCA loadings plot b) 
PCA 3D scores plot for fixed  tissue, Circled – separation of unknown spectra along PC2 c) 
PCA 2D scores plot with 95% confidence ellipses.  
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Differences between cancer and normal tissue separate most clearly along PC3, 
(Figure 19) with differences due to collagen; a variation which may be enhanced by 
fixation due to the increased presence of collagen in cancer tissue. The peak at 
1053cm-1 also suggests variation in the C-O and C-N stretching in proteins (Figure 
19a).(107) 
 
There is no identifiable clustering in the variation along PC1, when the tissue classed 
by the presence of cancer. However, the fixed tissue identifies differences between 
patients along PC1, with confidence intervals showing little overlap, when the 
tumours were classed based on the patients (Figure 17). There is some separation of 
some of the unknown spectra along PC2 (circled Figure 19b) and this appears to be 
due to differences in the CH3CH2 twisting in the collagen shown by the peak at 
1303cm-1 and in the purine bases of nucleic acids shown at the peak at 1328cm-1 
(Figure 19a).(107) Some of the differences along PC2 are also due to differences in 
the amide I and lipid regions.  A comparison to the classes in Figure 17 shows that 
these spectra were taken from patient 4. This area of clustering therefore, may be 
because patient 4 was the only patient with a stage IIb cancer; tumour >20mm and 
limited to the pancreas (T2) tumour but also involving local lymph nodes (Table 2). All 
other patients had larger (T3) tumours, with invasion of local tissues but not involving 
local lymph nodes (Table 2), which suggests Raman spectroscopy was able to identify 
and differentiate a tumour which had spread to lymph nodes from those which had 
invaded local tissues.   
 






Figure 20: PCA of blood sample, classed by patient (pt) and the addition of 60nm gold 
nanoparticles (+AuNP) for SERS measurements, a) PCA loadings plot, b) PCA 3D scores plot 
PCA analysis shows separation on PC1 which appear to be dependent on patient 
characteristics and separation on PC2 dependent of the addition of AuNP (Figure 
20b). The addition of  AuNP creates differences in the tryptophan or amide II range of 
peaks (Figure 20a).(107) Peaks at 1556cm-1 and 1563cm-1, showing the greatest 
contribution to PC2 on the loadings plot, don’t have a definite assignment to a 
chemical bond (Figure 20a). Interestingly, the greatest variation within a single 
patient occurs in patient 1, after the addition of AuNP (Figure 20b). This blood sample 
was the only sample of serum as opposed to whole blood, suggesting the addition of 
AuNP may have a greater impact in highlighting differences in serum due to sample 
preparation, potentially because of  the colour and optical properties of serum. 




Figure 21:PCA of fresh patient (pt) blood. A) PCA loadings plot b) PCA 3D scores plot with 
95% confidence ellipses 
 
SID:32164444  Hawwa A. Bham 
 99 
 
Figure 22:PCA of patient (pt) blood with 60nm gold nanoparticles added for SERS 
measurements (+AuNP). A) PCA loadings plot b) PCA 3D scores plot with 95% confidence 
ellipses 
 
Comparison of the scores plots shows that the general trends in the data are the 
same with and without the addition of AuNP; differences between patients are 
separated along PC1 and the heterogeneity in patient 1’s serum sample is separated 
along PC2 and PC3 (Figure 21b, Figure 22b). The addition of AuNP brings out a degree 
of separation between patients 2 and 3 along PC3 (Figure 22b). The average 
spectrum for blood samples with nanoparticles shows fewer clear peaks and a 
marginally lower intensity than blood samples without the addition of AuNP. This is 
surprising as the addition of nanoparticles ordinarily increases the Raman signal by 
creating hotspots. Patient differences are clearly evident from PCA of blood samples. 
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Differences between patients’ blood samples could be identified with and without 
the addition of nanoparticles. 
 
Spectra taken from a serum sample from patient 1, show more heterogeneity within 
the sample, both with and without the addition of AuNP (Figure 21b, Figure 22b). This 
could be due to the fact that it was the only serum sample whereas patients 2 and 3 
were whole blood samples. Equally, clinically, patient 1 was the only patient with a 
histologically undifferentiated (anaplastic or sarcomatoid) carcinoma, and so this 
clinical difference in tumour type may be reflected in the chemical properties of the 
patient’s blood, as a result of secretion or excretion of a tumour related compound 
into the patient’s blood. However, patient 2’s sample shows less heterogeneity than 
patient 3 and this was an undifferentiated carcinoma with osteoclast-like giant cells, 
whereas patient 3 had a ductal adenocarcinoma (Table 2). Histologically, both were 
moderately differentiated (grade 2), whereas the grade of differentiation is unknown 
for patient 1 (Table 2).  While a conclusion cannot be drawn from a single result, this 
would present an interesting opportunity with a much larger sample size to see if 
Raman spectroscopy could be used to predict or identify cancer types using serum 
samples, which could be pivotal in aiding and changing the diagnosis of pancreatic 
cancer, with the potential use of a much less invasive method.  
 
The use of both Raman and SERS shows differences between patients most clearly 
along PC1 (Figure 21b, Figure 22b). This variation appears to be associated with the 
same peaks regardless of the use of SERS. These differences appear to be due to 
peaks at 1552cm-1 and 1558cm-1, associated with tryptophan and at 1224cm-
1/1225cm-1 due to the b sheet structure of amide III (Figure 21a, Figure 22a).(107) 
The difference due to peaks at 1662cm-1 to 1676cm-1 are associated with differences 
in nucleic acid modes, cholesterol ester and C=C stretching or an amide I band (Figure 
21a, Figure 22a).(107) There is also peak at 1564cm-1/1565cm-1 which does not have 
a designated association.  
 
A comparison of loadings plots for fresh blood (figure 21a) and blood with AuNP 
(Figure 22a) shows where differences by patient type are identified differently based 
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on the addition of the nanoparticles; some peaks are enhanced by the addition of the 
nanoparticles, particularly along PC2 and PC3 (Figure 22a). The contribution of 
intensity of peaks to the variation is similar in samples with and without AuNP, but 
the PCA identifies and attributes the variation to different wavenumbers dependent 
on the use of SERS.  
 
In particular, the use of SERS highlights difference in peaks in the nucleotide 
conformation, cholesterol and DNA peaks along PC3 (Figure 22a).(107) The peak with 
greatest contribution along PC3, without the use of SERS, is at 1555cm-1, which is 
likely to be associated with variation within patient 1’s sample due to the presence of 
amide II. As there is separation between patient 2 and 3 along PC3, when using SERS, 
(Figure 22b) this could suggest the differences in interpatient differences in DNA and 
nucleotides are highlighted with the addition of AuNP. There is, however, also a 
spread of spectra, all taken from patient 1’s sample, along PC3 (Figure 22b). As these 
spectra have all been taken from the same patient, it is unlikely that the essential 
DNA in the sample is varied, but subtle variations between components of the blood 
or cells, may have been identified. The utility of these variations could be of limited 
importance, if the information simply identifies between blood components and cells 
types. However, if this was the case it could be expected that there would be greater 
spread of patient 2 and 3 spectra along PC3, as these samples were whole blood, 
which include red blood cells as well as serum components, and so the extra 
components should show greater heterogeneity of these samples than the serum 
sample. As this heterogeneity was not seen with the whole blood samples it could be 
inferred that the differences along PC3 are not simply due to differences in blood 
components. Therefore, as patients 1, 2 and 3 all had different types of cancer, 
understanding whether the variation in nucleotides and DNA is due to differences 
between the patients, or differences between their cancer types, could be of great 
potential significance.  
 
The spread of spectra along PC2, in both the fresh blood samples and those with 
AuNP, shows a spread within patients (Figure 21b, Figure 22b). The addition of AuNP 
was expected to give clearer spectra and acquire many different spectra, showing 
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where different components have been enhanced dependent on the presence of the 
nanoparticles.  In the fresh blood, the variation within patient samples, appears to be 
due to differences in the symmetric breathing of tryptophan, shown on the PCA 
loadings plot at peak 754cm-1, 966cm-1, phenylalanine thought to be at peak 1007cm-
1 and peak 1322cm-1 suggesting CH3CH2 deforming modes of collagen and the 
presence of nucleic acids (Figure 21a).(107) Further differences are shown due to 
peaks at 1609cm-1 thought to be associated with the presence of cytosine (NH2), 
1618cm-1 due to tryptophan and 1654cm-1 seen with a change in amide I (Figure 
21a).(107)  
 
The addition of SERS identifies variation due to different peaks, at wavenumbers  
777cm-1, 916cm-1, 1032cm-1, 1141cm-1 and 1154cm-1 and 1420cm-1 potentially 
attributed to phosphotidylinosotol, ribose vibration, CH3CH2 bending modes of 
collagen or the phenylalanine or proline of collagen, b carotenes and G,A in DNA/RNA 
or deoxyribose respectively (Figure 22a).(107) Peaks at 1635cm-1 (thought to be due 
to differences in collagen content), 1639cm-1, and 1643cm-1 are also identified, with 
the addition of AuNP (Figure 22a). There is also some overlap between wavenumbers 
thought to attribute to the variation identified in the fresh blood samples and those 
using SERS, at peak 1628/1629cm-1, associated with either C=C stretching or amide 
C=O stretching absorption in the b-form polypeptide films (Figure 21a, Figure 
22a).(107)  
 
These differences, along PC2, are likely to be differences in the blood components 
themselves, as there is a similar spread within each class, irrespective of the addition 
of AuNP. This is understandable as components such as b carotene (vitamin A), lipids, 
and proteins are components of blood which could be expected to vary dependent 
on the location in the sample from which the spectrum was taken.  
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5.6 Blood Vs resection  
 
Figure 23: PCA of blood and resection samples from patient 1 
 
Using PCA there was clear separation of blood spectra from resection spectra, with 
no overlap. This variation is expected as there are significant differences in the 2 
tissue types. Finding correlations between components of the tumour and blood, 
which might suggest secretion or excretion of a tumour component into the blood 
might make interesting further work. However, these correlations cannot be 
identified using PCA and may require alternative data analysis. 
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5.7 Histology  
 
a)  b)  
c)  d)  
e)  f)  
Figure 24:Histology images of cancerous resection tissue stained with haematoxylin and 
eosin a) patient 1 x10, b) patient 1 x40 c) patient 2 x10 d)patient 2 x 40 e)patient 3 x10 
f)patient 3 x40 
 
Haematoxylin and eosin staining shows the presence of stroma and morphology of 
cells in the tissue resections (Figure 24). The stroma is abundant in all resections. 
There is the visible presence of rounded cells with a large nucleus which are likely to 
be cancer cells as well as cells with a fibroblastic appearance, which are likely to be 
PSCs. There are no visible glands, which would also indicate the presence of cancer, 
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nor the presence of clear healthy pancreatic tissue, however the tissue was small and 
was unable to be sectioned to include both healthy and cancerous tissue.  
 
Immunohistochemical staining was also performed on the tissue, however this did 
not show the presence of any SPARC antigen (Appendix, Figure 40). However, it is 
likely that this was due to faults in the technique as opposed to the lack of SPARC in 
the tissue itself. Therefore, it would be necessary to optimise the 
immunohistochemistry technique for these samples, including altering antigen 
retrieval time and optimising the dilution of the antibodies.  
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Chapter 6 – Results and Discussion – Cell Lines  
The development of pancreatic cancer is an area which remains incompletely 
understood. Using 2D coculture models of HPAF-II and PSCs in varying proportions, 
Raman spectroscopy and ELISA are used to understand interactions between cancer 
cells and PSCs, identify changes to the cells and the quantify production of SPARC. 
Spectra taken from cocultured cell lines show potential to use Raman spectroscopy to 
identify differences between cell types as well as demonstrate changes which may 
occur due to the coculture environment.  
 
Cocultures of HPAF-II and PSCs were set up with cells in direct and in indirect contact, 
at proportions of HPAF:PSC 25:75, 50:50 and 75:25 (Figure 25). Those in indirect 
contact were grown in a wells plate using a permeable insert, meaning cells could 
share media but there was no direct contact between cells. Spectra were taken from 
cells grown on CaF2 slides and were pre-processed using baseline correction 
(polynomial order 6) and vector normalisation, before being analysed using PCA. 
  
These results analyse interactions and relationships between cell types in different 
environments and at different proportions. The data suggests biochemical changes 
are occurring in cells dependent on their coculture environment and interactions, 
giving further insight into the development of pancreatic cancer and suggesting 
pathways which might stimulate or inhibit these changes. It aims to identify what 
some of these biochemical changes might be using Raman spectroscopy and creates 
a model and basis for further research into pancreatic carcinogenesis and 
progression.  
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Figure 25:Diagram showing set up of coculture HPAF-II:PSC 25:75 in direct and in indirect 
contact. The same set up was used for HPAF:PSC 50:50 and 75:25 proportions. Spectra were 
taken from cells on CaF2 slides. 
 
Wells plate insert 
containing 25% HPAF-II 
cells 
75% PSCs grown on CaF2 
slide  
Wells plate insert 
containing 75% PSCs 
25% HPAF-II grown on 
CaF2 slide  
HPAF-II and PSCs grown 
in 25:75 proportion on 
CaF2 slide 
Cells in Direct contact 
Cells in Indirect contact 
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6.1 Cell Cocultures  
a)  
b)  
Figure 26:PCA analysis of all cells. a) PCA loadings plot, b) PCA 3D scores plot. ‘Indirect’’ 
indicates cells grown in coculture in a wells plate, with cells sharing media but no contact 
between the cells. 
 
PCA of all cell cocultures, those grown in direct and indirect contact at all 
proportions, shows substantial overlap of groups. There is a similar pattern of 
variation along both PC1 and PC3, showing separation between groups of cells(Figure 
26b). Separation along PC2 is less pronounced and shows heterogeneity within HPAF-
II grown in a 25:75 (HPAF:PSC) coculture in a wells plate and within one group of 
100% HPAF-II cells (Figure 26b). The relationship between the cell types appears to 
have some impact as the greatest separation along both PC1 and PC3 is between the 
HPAF-II grown alone and those grown in a 25:75 (HPAF:PSC) coculture in a wells 
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plate, with no contact between cells. HPAF-II and PSCs grown in 75:25 (HPAF:PSC) 
coculture in contact on a slide, show the greatest separation within their own group 
and greatest overlap with all other cells groups(Figure 26b).  
 
Separation is seen mostly along PC1 and PC3, and attributed to differences in peaks 
associated with changes to a CH2 bond (1439cm-1,1442cm-1, 1445cm-1, 1449cm-1) as 
well as a C-H vibration in either proteins or lipids (1449cm-1) and CH2/CH3 
deformation of lipids and collagen or deoxyribose (1460cm-1) (Figure 26a).(107) It is, 
however, difficult to identify the degree to which this separation is due to inherent 
differences between PSCs and HPAF-II cells because they are different cell types or an 
impact of the coculture. 
 
6.2 HPAF-II versus Pancreatic Stellate Cells 
Comparison of slides containing either 100% HPAF-II or 100% PSC, shows the innate 
differences between the 2 cell types. On initial PCA analysis, PSCs show greater 
heterogeneity than HPAF-II cells, although there is some overlap between 4 HPAF-II 
spectra and the general cluster of PSCs (circled Figure 27b). The cell types vary along 
PC1 with greatest difference in the symmetric ring breathing mode of phenylalanine 
(1001cm-1) and CH2CH3 deformation or collagen (1448cm-1) (Figure 27a).(107) There is 
also separation along PC2 of stellate cells when grown as part of the wells plate 
experiment as opposed to the slides, but also within the group grown on the wells 
plate, which shows greater differences of spectra within a single class than any other 
group of cells (Figure 27b). The heterogeneity highlighted by PC2 is due to 
phenylalanine (peak 1001cm-1) and some contribution from peaks in the range 
1631cm-1 to 1654cm-1, associated with collagen content (1635cm-1), and amide I 
(1643cm-1, 1646cm-1, 1654cm-1) (Figure 27a).(107)This is surprising as both slides 
contained only PSC, grown in the same conditions, with no other external influencing 
factors. The only difference between the 2 sets of PSC was the passage at which the 
experiment was conducted, which could be a contributing factor as the PSC are a 
primary cell line and so may be sensitive to biochemical changes, if not morphological 
ones, with a greater passage. 





Figure 27:PCA analysis of 100% HPAF and 100% pancreatic stellate cells. a) PCA loadings 
plot b) PCA 2D scores plot. Overlap between 4 HPAF-II spectra and the general cluster of 
PSC is circled. ‘Indirect’’ indicates cells grown in coculture in a wells plate, with cells sharing 
media but no contact between the cells. 
 
 





Figure 28:PCA-LDA analysis of 100% HPAF and 100% pancreatic stellate cells. a) PCA 
loadings plot b) PCA-LDA 2D scores plot c) PCA-LDA 1D scores plot. ‘Indirect’’ indicates cells 
grown in coculture in a wells plate, with cells sharing media but no contact between the 
cells. 
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PCA-LDA analysis separates the HPAF-II cells much more distinctly, although there is 
still much more heterogeneity among the PSCs and some overlap of these cells with 
the HPAF-II (Figure 28b, Figure 28c). This may be because the spectra have been 
taken of fundamental components present in both cells, such as cell membrane, and 
the structure of these components is essentially the same across cell types. Similarly 
to PCA, the separation between the cell types can be seen along LD1, with the 
heterogeneity of the PSC cells grown in wells plates seen along LD2. Using PCA-LDA 
analysis also brings out greater heterogeneity in the HPAF-II cells grown for 
experiments with cells grown in indirect contact; a separation also seen along LD2 
(Figure 28b).  
 
PCA-LDA attributes the separation between the cell types to amide III, adenine, 
cytosine (1258cm-1), guanine (1356cm-1), an C=O symmetric stretch (1398cm-1) and a 
CH2 bending mode or scissoring (1439cm-1) (Figure 28a).(107) The greatest 
contribution to the variation, according to the PCA-LDA, appears to be due to a peak 
at 1432cm-1, although this is not a true peak which can be identified in the raw 
spectra.  
 
The separation within the groups of HPAF-II and PSC, seen along LD2 appear to be 
due to phenylalanine (1000cm-1) or differences in collagen content, (1635cm-1) 
(Figure 28a).(107) The peak at 1659cm-1 could be due to amide I vibration of collagen 
like proteins, amide C=O stretching absorption or glutathione.(107) These are 
expected differences between HPAF-II and PSCs as phenylalanine is a component of 
DNA and amide I is a protein, which are likely to differ because of essential 
differences in the phenotype of cells. The difference identified in collagen is also a 
known difference as PSCs are able to produce ECM proteins, including collagen, 
whereas cancer cells do not have this function.(108)  
 
SID:32164444  Hawwa A. Bham 
 113 
6.3 Cocultures in Direct Contact  
a)  
b)  
Figure 29:PCA analysis of cells in direct contact a) PCA loadings plot b) PCA 3D scores plot 
 
Similarly to the PCA of uninfluenced HPAF-II and PSCs, the cocultures also show 
differences in phenylalanine, however it can be assumed that this is due to an innate 
difference between the cell types and not a result of the influence of the coculture 
environment. The variation along PC1 can also be seen due to C-H vibration in protein 
or lipid at peak 1449cm-1, a cholesterol or lipid band seen at 1444cm-1, deoxyribose 
associated with peak 1455cm-1 and differences in nucleic acid modes at peak 1458cm-
1 (Figure 29a).(107) The comparison of uninfluenced HPAF-II with PSC showed a peak 
at 1448cm-1 which may have shifted to 1449cm-1 as a result of coculturing the cells, 
suggesting in cocultured cells there is more variation due to C-H vibration than due to 
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CH2CH3 deformation or collagen. Given this shift it could also be assumed that the 
innate difference between HPAF-II and PSCs is due to the CH2CH3 deformation as 
opposed to collagen content.  Variation due to peaks at 1444cm-1, 1455cm-1 and 
1458cm-1 appear to have arisen as result of the influence of coculture (Figure 29a), 
suggesting coculturing cells causes changes to the expression or function of the cells.  
 
Both PC2 and PC3 identify variation within the groups. As there is a similar pattern of 
separation within all groups, these peaks are possibly associated with differences 
between components or organelles common to all cells, dependent on the location 
within the cells from which the spectra were taken. Differences along PC2 are 
attributed to phenylalanine (1002cm-1), lipids (1652cm-1) and variations in the amide I 
band (1660cm-1, 1626cm-1, 1636cm-1) (Figure 29a),(107) all of which are likely to vary 
in their presence and quantity dependent on the organelle or location in the cell from 
which the spectrum is acquired; it is feasible that PC2 identifies this natural variance 
within a cell. While the pattern of separation along PC2 and PC3 are similar, there is a 
greater spread of the data along PC3 than PC2. The most significant contribution to 
this spread is phenylalanine (1002cm-1, 1034cm-1) and amide I (1636cm-1), which are 
also seen in PC2 (Figure 29a).(107) PC3 also identifies variation due to DNA and 
phospholipids (1330cm-1) (Figure 29a).(107)   
 
6.4 Cocultures in Indirect Contact  
HPAF-II and PSCs, grown in indirect contact, separate mostly along PC1, with HPAF-II 
100% cells separating from all other cells along PC2 (Figure 30b). There is significant 
overlap between spectra taken from HPAF-II grown at 50%, 75% and 100% 
proportions. HPAF-II cells grown at 25%, in coculture with 75% PSC, however, 
separate completely from all other HPAF-II groups, along PC1, separating even 
further than the groups of PSCs (Figure 30b). The PSCs from the same the coculture, 
on the other hand, show some overlap with the other groups of HPAF-II cells. 
Although they still overlap with the PSCs, there is much greater overlap with the 
HPAF-II cells.  
 




Figure 30:PCA analysis of cells in indirect contact, grown in a wells plate with an insert, . 
‘Indirect’’ indicates cells grown in coculture in a wells plate, with cells sharing media but no 
contact between the cells,  a) PCA loadings plot b) PCA 2D scores plot 
 
This suggests that cells grown in indirect contact at a proportion of HPAF:PSC 25:75, 
have an influence on each other, creating differences in the HPAF-II cells by altering 
the backbone geometry and phosphate ion interactions (peak 799cm-1), 
phenylalanine (1001cm-1),  CH2CH3 deformation (1448cm-1, 1451cm-1) and an amide I 
a-helix (1658cm-1) (Figure 30a), although some of this variation is natural variation 
between HPAF-II and PSCs (Figure 27).(107) The differences between HPAF-II and PSC 
cells also appear to be due to the same peaks, as these also vary along PC1, 
suggesting that at a HPAF:PSC 25:75 proportion, the products secreted by PSCs and 
the subsequent interactions cause HPAF-II cells to change their phenotype to become 
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more similar to PSCs. It is difficult, however, to identify whether these changes are 
due to the proportions at which the cells are cocultured or the indirect nature of the 
interaction between the cell types.  
 
The HPAF-II 100% cells separate from all other cell types, both HPAF-II grown in 
coculture and all PSCs, along PC2 (Figure 30b). This is mostly due to a difference in 
phenylalanine (1002cm-1) and an amide I band and a-helix (1643cm-1, 1646cm-1, 
1654cm-1, 1656cm-1)(Figure 30a).(107) This suggests that in comparison to ‘pure’ 
HPAF-II cells, those which interact indirectly with PSCs, change their phenotype to 
some degree, through changes to phenylalanine and amide I, to become more similar 
to PSCs, although they can still be identified as a distinct group.  
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6.5 Comparison by Proportion  




Figure 31:PCA analysis of cells grown at HPAF:PSC 25:75 proportions in direct contact and 
indirect contact. ‘Indirect’’ indicates cells grown in coculture in a wells plate, with cells 
sharing media but no contact between the cells a) PCA loadings plot b) PCA 2D scores plot, 
c) PCA 1D scores plot 
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Variation amongst cells grown at HPAF:PSC 25:75 can be seen entirely along PC1. 
There is clear separation of the HPAF 25% group, grown in indirect contact with PSC 
75%, and more overlap between HPAF:PSC 25:75 grown in direct contact and the 
PSCs 75% (Figure 31c). This may suggest that indirect contact with PSCs increases 
variation in HPAF-II cells at a 25:75 proportion, more so than direct contact between 
the cells at the same proportion. This is surprising as it was hypothesised that the 
greater variety would be seen in cells growing in direct contact as there is both direct 
and indirect contact between these cells and so this would have a greater influence 
than just indirect contact. It may, however, suggest that there is a more complex 
relationship between the two cell types, with some pathways which may be inhibited 
by the direct contact between cells. Thus, the impact of such pathways is amplified 
when cells are grown in indirect contact, causing more alterations to the HPAF-II cells 
grown in indirect contact with PSCs than those in direct contact.  
 
PCA suggests that some of the variation along PC1 is due to natural variation 
between PSCs and HPAF-II cells; peaks at 799cm-1, 1001cm-1 and 1448cm-1 were seen 
on the loadings plot when comparing uninfluenced HPAF-II with uninfluenced PSCs 
(Figure 28a, Figure 31a). Growing cells in coculture, however, has identified further 
differences due to new peaks associated with changes to CH2 (1302cm-1) and amide I 
(1658cm-1, 1660cm-1, 1667cm-1), which would suggest that these differences are a 
result of the influence of interaction between cells (Figure 31a).(107) 
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6.5.2 HPAF:PSC 50:50 
 
Figure 32:PCA analysis of cells grown at HPAF:PSC 50:50 proportions in direct contact and 
indirect contact, ‘Indirect’’ indicates cells grown in coculture in a wells plate, with cells 
sharing media but no contact between the cells a) PCA loadings plot b) PCA 3D scores plot 
Along PC1, there is clear separation between HPAF-II and PSC, with spectra from the 
slide with HPAF:PSC 50:50 grown in direct contact showing an even spread along PC1, 
overlapping with both of the individual cell types (Figure 32b). This is expected as this 
slide contained both cell types and so the PC1 spread would suggest that PCA is able 
to separate out these cell types. There is also some separation between cell types 
along PC3 (Figure 32b). The loading plot suggests that much of this variation is due to 
natural variation between the cell types but peaks the peak at 1306cm-1, associated 
with changes to CH2, is due to the influence of the interaction between the cells 
(Figure 32a). This is a similar variation identified as a result of interaction of cells at a 
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25:75 proportion, which may suggest that coculturing HPAF-II and PSCs in any 
proportion causing changes in CH2 groups in one or both of the cell types.  
 
PC2 shows the heterogeneity within the PSC 50%, grown in indirect contact with 50% 
HPAF-II (Figure 32b). This degree of heterogeneity within the cell type is only seen in 
the cells grown in indirect contact and is not present in what could be assumed to be 
PSCs, based on their separation along PC1, from the cells grown in direct contact. This 
would suggest either, that being grown in direct contact with cancer cells reduces a 
natural heterogeneity present within PSCs, or growing PSCs indirectly in contact with 
cancer cells causes an interaction which allows them to proliferate in a way that 
creates this heterogeneity but which may be inhibited by the direct presence of 
cancer cells. Alternatively, this heterogeneity may be a difference in the PSCs 
themselves, potentially due to differences in passage, as was seen in PCA of 100% 
HPAF-II and 100% PSCs.  
 
Some of the heterogeneity within the PSCs 50% in indirect coculture is also identified 
along PC3 (Figure 32b). PC3 also shows much more separation within the HPAF:PSC 
50:50 group grown in direct contact, with some spectra showing very clear overlap 
with the HPAF-II 50% and the remaining spectra showing a similar pattern of 
heterogeneity as the PSC 50% group. As the PSCs showed greatest heterogeneity 
when uninfluenced (Figure 27b), this would suggest that some of this heterogeneity 
is natural. However, the coculture does appear to have an influence on the nature of 
the heterogeneity as when cocultured PCA attributes the differences to peaks at 
783cm-1, ns COO- possibly in IgG (1406cm-1), C=C in amide I (1650cm-1) and 1661cm-1 
along PC2 and phosphodiester (812cm-1), polysaccharide structure (841cm-1), a CH2 
bending mode in malignant tissue (1450cm-1), CH2CH3 deformation (1451cm-1) along 
PC3 (Figure 32a).(107) Whereas, the PCA of PSCs not in coculture suggest the 
heterogeneity is due to peaks at phenylalanine (1001cm-1) and CH2CH3 deformation 
or collagen (1448cm-1) (Figure 13a).(107) These results suggest that growing cells in 
coculture with indirect contact can have an influence on the cell phenotype. The fact 
that this heterogeneity is highlighted in cells in indirect contact and not those grown 
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in direct contact also suggests there may be a degree of inhibition which is more 
influential when the cells are in direct contact.  
 
6.5.3 HPAF:PSC 75:25 
a)  
b)  
Figure 33:PCA analysis of cells grown at HPAF:PSC 75:25 proportions in direct contact and 
indirect contact, ‘Indirect’’ indicates cells grown in coculture in a wells plate, with cells 
sharing media but no contact between the cells a) PCA loadings plot b) PCA 3D scores plot 
 
HPAF-II 75% cells when grown in indirect contact with PSC 25%, separate as a very 
distinct group along PC1, whereas there is overlap between the HPAF:PSC 75:25 
grown in direct contact and PSCs 25% (Figure 33b). The distribution of spectra and 
classes along PC1 is very similar to the distribution of HPAF:PSC at a 25:75 proportion, 
with the HPAF cells grown in indirect contact with PSCs showing clear separation 
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from cells grown in direct contact, while PSCs show an expected overlap (Figure 31b, 
Figure 33b).  While this could be because more spectra were taken from PSCs than 
HPAF-II on the slide, it could also suggest that the direct contact of HPAF-II and PSCs 
grown at this proportion causes changes to HPAF-II cells giving them characteristics 
similar to that of PSCs. Alternatively, indirect contact may allow for a change to HPAF-
II cells which is otherwise inhibited by the direct contact between cells. PCA suggests 
these changes to the HPAF-II cells are in phenylalanine (1001cm-1) CH2 scissoring 
(1436cm-1, 1439cm-1, 1445cm-1) a CH2 bending mode found in malignant tissues 
(1450cm-1), a protein band (1453cm-1) (Figure 33a).(107) The peak at 1445cm-1 may 
be particularly significant as it has been shown to be associated with a number of 
changes to CH2 and CH2CH3 bonds, in both proteins and lipids, some of which have 
been shown to be of diagnostic significance in normal and cancerous tissue of the 
nasopharynx.(107)  
 
Comparison of the PCA scores plots, with cells grown at different proportions, shows 
differences in the way spectra taken from HPAF-II cells in indirect contact, as opposed 
to those grown in direct contact, separate and cluster along PC1. HPAF-II cells grown 
in indirect contact at a HPAF:PSC 25:75 and 75:25 proportion cluster separately to 
cells grown in direct contact, whereas those at a 50:50 proportion overlap (Figure 
31b, Figure 32b, Figure 33b). It is unlikely that this separation of HPAF-II cells grown 
in indirect contact is simply because more spectra have been taken from PSCs on the 
slides with cells in direct contact, as the probability of doing so on a slide containing 
75% HPAF-II cells is low. Therefore, coculturing HPAF-II and PSCs appears to have an 
impact on the cancer cells which causes some changes to their phenotype. However, 
as this separation of HPAF-II cells is not present at a HPAF:PSC 50:50 proportion, 
which makes it difficult to propose the type of change or reason they may occur.  
 
The HPAF-II 75% group also clusters along PC3 but this cluster sits in the middle of 
spectra acquired from PSC 25% grown in indirect contact (Figure 33b). Along both 
PC1 and PC3 there is almost no overlap between HPAF-II 75% and HPAF:PSC 75:25, 
grown in direct contact, supporting the hypothesis that either direct contact with 
PSCs causes changes to HPAF-II as a result of the contact and direct interaction of the 
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cells or the indirect contact allows for changes to HPAF-II cells which are inhibited 
through direct contact between cells.  
 
There is more heterogeneity of the PSC 25% along PC3 and the spectra from these 
cells overlap with all other cell types (Figure 33b). Similarly to cocultures in other 
proportions the PCA would suggest that in part this heterogeneity is a result of the 
influence of the coculture, as opposed to natural variance in the cells, as the peaks 
identified as causing these differences are different to those identified in the initial 
PCA of uninfluenced PSCs (Figure 28a, Figure 33b). 
 
In comparison to the PCA loadings plot of the HPAF:PSC 50:50 coculture, which 
identified heterogeneity of PSC along PC2, (Figure 32a) changing the proportion of 
cells to HPAF:PSC 75:25 identifies differences along PC3 (Figure 33). It identifies the 
heterogeneity attributed to peaks in the nucleotide conformation (704cm-1), C-C 
stretching (929cm-1), guanine (1336cm-1) and n(C=C) in tryptophan or porphyrin 
(1618cm-1) (Figure 33a). Interestingly, when the proportion of cells is changed from 
50:50 to 75:25, the peaks attributed to causing heterogeneity within the cells change 
and there is no overlap between the peaks identified for the 2 proportions.  
 
SID:32164444  Hawwa A. Bham 
 124 
6.6. Cells and Tumour  
Spectra taken from cell line cocultures were compared those taken from cancerous 
tumour tissue, taken from patient 1, to identify overlaps in the spectra, which shows 
which models were most similar to human tissue and so could be most useful for 
further research. Identifying differences between the models and tissue also 
identifies elements of the model which may need to be altered to create a model 
which functions most similarly to human tissue,  working towards developing a model 
which allows for research that is more easily translated to clinical practice.  
a)  
b)  
Figure 34:PCA comparing cells line models with cancerous tissue. ‘Indirect’’ indicates cells 
grown in coculture in a wells plate, with cells sharing media but no contact between the 
cells Spectra for cancer tissue were taken from fresh tissue from patient 1. a) PCA loadings 
plot b) PCA 3D scores plot 
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There is overlap between spectra taken from the tumour and the cell lines and in 
particular any spectra taken from HPAF-II cells, at any proportion other than HPAF 
25%, along both PC1 and PC2 (Figure 34b). This is unsurprising as the tumour is likely 
to contain a significant proportion of cancer cells. There is much less overlap with the 
PSCs, which are ordinarily present in the tumour stroma, suggesting that the natural 
tumour environment alters these PSCs in a way which has not been replicated by the 
cell line models.  
 
The tumour tissue separates very clearly along PC3, due to differences in skeletal 
modes including polysaccharides and amylose (940cm-1, 943cm-1), phenylalanine 
(protein assignment) (1602cm-1) and cytosine (NH2) (1610cm-1) (Figure 34a),(107) 
which suggests there are factors in vivo which create these differences which have 
not been replicated by simply growing the relevant cell types in coculture.  
 
This may in part be a result of the fact that patient 1 had an undifferentiated 
(anaplastic or sarcomatoid) carcinoma whereas HPAF-II cells are a PDAC cell line 
(Table 2). However, there is much more similarity between the tumour spectra and 
HPAF-II spectra, and the differences are in the PSCs. This suggests that cancer cells, 
even in different histological types of pancreatic cancer, are similar, whereas their 
interaction with and impact on PSCs differs, in part dependent on the tumour type. 
This highlights the complexity and importance of the relationship between cancer 
cells and PSCs and emphasises the need for a better understanding of these 
interactions, in the development and progression of pancreatic cancer, in order for 
there to be developments in research which will be successful when applied in a 
clinical  setting.  
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6.7 SERS – mapping image analysis  
Surface enhanced Raman spectroscopy (SERS) was used on cocultured cells, using the 
mapping set-up in a raster pattern, taking spectra every 5µm. Initial analysis showed 
great variety in peaks, dependent on the presence of nanoparticles, suggesting that 
SERS can identify very subtle changes within cells and extract specific organelle 
information in great detail.  
 
The outline of the cells and presence of nanoparticles can be seen on the white light 
images (Appendix, Figure 41). The morphology of the cells was clearer when looking 
down the microscope than can be seen in the images, which allowed good 
visualisation of the cells and nanoparticles, which is obscured on the images due to 
the camera quality. Initial shading by PCA shows variation to be independent of the 
visible distribution or concentration of nanoparticles on the image (Figure 35). Darker 
shading showed visually higher signal to noise ratio, suggesting these were areas 
where nanoparticles had interacted with components of the cell, giving very specific 
organelle data. However, it is difficult to determine whether the variation seen is due 
to the presence of nanoparticles or differences within the cells. Moreover, as PCA is 
carried out on each image separately, it is not possible to compare and identify 















Figure 35:Raman shaded maps for cell cocultures with SERS showing shading by PCA. PC1 is 
seen in magenta and PC2 in yellow Scale bar 20µm. Maps were taken from 2 locations on 
each slide a) HPAF 25:75, b) HPAF 50:50, c) HPAF 75:25, d)HPAF 100% e) PSC 100% 
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Further, signal to baseline analysis identified regions according to specified peaks. 
The 600-800cm-1 and 1325-1345cm-1 ranges were used, both highlighting differences 
associated with DNA (Figure 35). Shading using 5-95% of the peak intensity range was 
used to reduce contribution from spectra with very low and very high intensity 
including regions where the receptor had been saturated, in turn highlighting SERS 
spectra.  
 
ai)  aii)  
bi)  bii)  
ci)   cii)  
di)  dii)  
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ei)  eii)  
 
Figure 36: Raman shaded maps for cell cocultures grown in direct contact with SERS 
showing shading by signal to baseline analysis  for wavenumbers i) 600-800cm-1 and 
ii)1325-1345cm-1. Colour bar shown as reference for shading; blue shows lowest relative 
intensity and red the highest relative intensity within the image but shading is arbitrary 
and not numerically equal or comparable between images. Scale bar 20µm. ai) HPAF:PSC 
25:75 600-800cm-1 shading aii) HPAF:PSC 25:75 1325-1345cm-1 shading , bi) HPAF 50:50 
600-800cm-1 shading bii) HPAF:PSC 50:50 1325-1345cm-1 shading, ci) HPAF:PSC 75:25 600-
800cm-1 shading cii) HPAF:PSC 75:25 1325-1345cm-1 shading, d)HPAF 100% 600-800cm-1 
shading dii)HPAF 100% 1325-1345cm-1 shading ei) PSC 100% 600-800cm-1 shading eii) PSC 
100% 1325-1345cm-1 shading 
 
Shading by signal to baseline, allows some identification of regions of DNA. 
Comparison of images shaded by signal intensity of 600-800cm-1 and those shaded by 
the signal intensity of 1325-1345cm-1 ranges show overlap, particularly where the 
relative intensity is highest (Figure 36, Appendix, Figure 42). This shading therefore 
allows us to identify the location of the nuclei, based on the areas of high DNA 
intensity. However, what is difficult to identify are the changes to the spectra within 
each of the chosen regions of wavenumbers, which is likely to be more pertinent 
information in understanding the changes to the DNA which have occurred as a result 
of the coculture environment and so in understanding the impact the coculture on 
the cells. As shading is according to regions, changes within these regions are not 
evident.  
 
While shading according to the intensity of a single peak and identifying how the 
presence of a single peak changes between images may show the changes in 
intensity within a single peak, this would reduce the amount of information seen 
within an image and risks missing information. Subtle shifts in the peak, which could 
highlight important information about cellular changes, would not be viewed on an 
image shaded by peak intensity and so could not be differentiated from peaks which 
SID:32164444  Hawwa A. Bham 
 130 
are of less significance. Moreover, it is difficult to know if low signal intensity, in a 
particular location, is because the relevant cell structure is not present in that 
location or due to insufficient presence of nanoparticles.  
 
While regions of highest intensity overlap between images, what appear to be 
background regions on the image when shaded to 600-800cm-1 showing very low 
intensity, when shaded to 1325-1345cm-1 show higher intensity (Figure 36, Appendix, 
Figure 42). This may be because a number of peaks in the 1325-1345cm-1 are possibly 
associated with both nucleic acids and CH2CH3 wagging in collagen as well as the 
presence of phospholipids. If lower intensities, seen in the background, are 
identifying collagen this may suggest the beginnings of collagen deposition when 
coculturing the cells. However, there is little difference in the relative background 
intensities between different coculture proportions, which makes it difficult to 
propose how the coculture environment may be having an impact on any potential 
collagen deposition. Shading so the intensities are of numerical equivalence between 
images may give more insight into this, as it would allow for a direct comparison 
between different coculture proportions. This is difficult using the WiRE software, 
without arbitrarily altering the peak intensity range used, which could remove 
potentially important information.  
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ai)  aii)  
bi)  bii)  
ci)  cii)  
di)  dii)  
ei)  eii)  
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fi)    fii)  
gi)   gii)  
hi)   hii)  
 
Figure 37: Raman shaded maps for cell cocultures grown in indirect contact with SERS 
showing shading by signal to baseline analysis  for wavenumbers i)600-800cm-1 and ii) 
1325-1345cm-1. Colour bar shown as reference for shading; blue shows lowest relative 
intensity and red the highest relative intensity within the image but shading is arbitrary 
and not numerically equal or comparable between images. Scale bar 20µm. ai) HPAF 25% 
600-800cm-1 shading aii) HPAF 25% 1325-1345cm-1 shading , bi) HPAF 50% 600-800cm-1 
shading bii) HPAF 50% 1325-1345cm-1 shading, ci) HPAF 75% 600-800cm-1 shading cii) HPAF 
75% 1325-1345cm-1 shading, d)HPAF 100% 600-800cm-1 shading dii)HPAF 100% 1325-
1345cm-1 shading ei) PSC 100% 600-800cm-1 shading eii) PSC 100% 1325-1345cm-1 shading, 
fi) PSC 25% 600-800cm-1 shading fii) PSC 25% 1325-1345cm-1 shading , gi) PSC 50% 600-
800cm-1 shading gii) PSC 50% 1325-1345cm-1 shading, hi) PSC 75% 600-800cm-1 shading hii) 
PSC 75% 1325-1345cm-1 shading. 
 
SID:32164444  Hawwa A. Bham 
 133 
Shading by signal to baseline for 600-800cm-1 and 1325-1345cm-1 for cells grown in 
indirect contact, showed greater differences than those grown in direct contact 
(Figure 37, Appendix, Figure 43). Although, there was some overlap between areas of 
highest relative intensity of the two regions, there were a number of locations 
showing highest intensity of wavenumber in the 600-800cm-1 region, which showed 
the lowest intensity of 1325-1345cm-1; a difference which was not as apparent in the 
images of cocultures grown in direct contact (Figure 37, Appendix, Figure 43). 
Interestingly, the areas of highest intensity for 600-800cm-1 are often adjacent to 
areas with highest 1325-1345cm-1 intensity. This may suggest, in a single cell type, 
shading may be identifying differences within the nucleus based on differences 
between the nucleotide conformation and in nucleic acids. In contrast, the coculture 
of more than one cell type obscures this variation, potentially because of the 
interaction and attachment between cells impacting the distribution, especially 
where cells may grow on top of each other due to lack of space, or by causing 
changes to the DNA.  
 
Much like the shading for cocultures grown in direct contact, the background when 
shaded according to signal of the 1325-1345cm-1 region, shows a higher relative 
intensity than the background with maps shaded to 600-800cm-1 (Figure 37, 
Appendix, Figure 43). There is however, much more variation in this background 
intensity in the single cells, although it is difficult to compare between images of 
different coculture proportions to determine the significance of this difference.  
6.8 ELISA 
Quantitative ELISA showed cells grown in indirect contact to produce much more 
SPARC than those grown in direct contact. In line with the literature, HPAF-II cells 
grown alone did not produce any SPARC, confirming that it is the PSCs in pancreatic 
tumours responsible for SPARC production (Figure 38).(44, 49, 50) PSCs alone also 
produced very little SPARC, compared to the production in cocultures, suggesting 
that the interaction between PSCs and HPAF-II stimulates SPARC production. This 
stimulation appears to occur regardless of whether the cells are in direct or indirect 
contact.  
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The significantly greater production of SPARC by cells grown in indirect contact may 
in part be a result of a higher seeding density and differences in passage of the 
stellate cells, when setting up coculture experiments. Alternatively, similarly to the 
variance seen in the PCA of the Raman spectra of cocultured cells,  the direct contact 
between cells may inhibit cell proliferation and SPARC production in a way which 
does not occur when cells interact indirectly.  
 
The serum sample (from patient 1) contained the highest concentration of SPARC, 
and very similar concentration to cells grown in indirect contact at HPAF:PSC 50:50 
proportion (Figure 38). For cells grown in indirect contact, a 50:50 proportion 
produces the highest SPARC concentration, and for those grown in indirect contact 
25:75 proportion produces the highest SPARC concentration, although the standard 
deviation bars suggest the 25:75 in indirect contact could produce more SPARC than 
a proportion 50:50 in indirect contact (Figure 38). Given the size of the standard 
deviation bars, especially for the 25:75 grown in indirect contact, further repeats may 
need to be done to validate these results.  
 
Figure 38: Bar chart, with standard deviation bars, showing SPARC concentration values 
using quantitative ELISA, from media from cell cocultures and serum from patient 1. ‘w’ 
indicates media taken from cocultures grown in indirect contact in wells plates with an 
insert.  
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Chapter 7 – Discussion  
Raman spectroscopy has been used to identify a number of cancers, both at a 
diagnostic stage and during surgery to guide resection.(84, 91) However, the 
literature gives little insight into its potential use in pancreatic cancer. There has been 
very little research into identifying differences between cancerous and healthy tissue 
in pancreatic cancer using Raman spectroscopy and all of the current literature 
differentiating healthy pancreas from that which is diseased does so using animal 
models.(95, 96) There is some work aiming to identify a serum biomarker for 
pancreatic cancer, however, this is largely focussed on the development of 
nanoparticles and immunoassays to improve sensitivity and specificity, particularly of 
the MUC4 marker, as opposed the identification of a novel biomarker.(28, 92-94)  
 
This study investigates the utility of Raman spectroscopy in differentiating healthy 
pancreas from cancers of the exocrine pancreas, using both human tissue and blood 
samples, ultimately aiming to identify novel biomarkers which could be used in 
screening, diagnosis or in the surgical guidance of resection margins. It further 
investigates the ability of Raman spectroscopy and SERS, to identify and provide 
information about the characteristics of pancreatic cancer, with a focus on cancer 
cells and PSCs and their interactions, in a 2D cell line model.  
 
7.1 Importance of Collagen in Differentiating Healthy and Cancerous Tissue   
Variation between cancerous and healthy tissue, in fresh tumours of the same 
pathological staging, is seen due to differences in proline and presence of nucleic acid 
in the tissue, and identified due to differences in collagen in fixed tissue. As PCA-LDA 
identified that collagen is most altered during the fixing process, the differences in 
collagen seen after accounting for differences in sample preparation may suggest 
that the composition and quantity of collagen varies between healthy and cancerous 
tissue, and potentially even between tumour types, in a way that is related to and 
allows identification of the malignant nature of the tissue. This variation, due to 
collagen, may be enhanced on PCA when tissue is fixed, as the cross-linking of 
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proteins caused by fixing has a greater impact on collagen proteins than other 
components in the tissue, therefore highlighting differences in the cancer which are 
caused by collagen.(85, 100) The higher intensity of the collagen peak in fixed 
cancerous tissue is visible on the pre-processed spectra.   
 
The role and presence of collagen in pancreatic cancer is already well described in the 
literature. It is understood that human PDAC tumours have a high collagen content, 
with one study suggesting approximately 41% of the tumour area is composed of 
collagen in human sections.(109) In the healthy pancreas specific organized 
expression of collagen is needed for maintenance of epithelial structure and for 
healthy organ function and maintenance. However, pathological deposition of 
collagen causes fibrosis and plays a role in pancreatic carcinogenesis.(110) This study 
suggests that Raman spectroscopy may able to identify this excess deposition and 
change in collagen, which could in turn be used to identify tumour margins, and in 
the diagnosis of pancreatic cancer.  
 
Importantly, pancreatic cancer cells increase Snail expression, in response to contact 
with collagen type 1, and Snail expression has been shown to be a regulator of EMT, 
an early and important change in the development of pancreatic cancer.(110, 111) 
Hence, the presence of collagen is an early feature in the development of pancreatic 
cancer and one which promotes the development and progression of pancreatic 
cancer. An ability to accurately and sensitively identify collagen presence at a stage 
when it is promoting EMT, a precancerous lesion, may allow for the development of a 
method which enables earlier detection of pancreatic cancer. Collagen alignment is 
also positively correlated with EMT expression and high collagen alignment has been 
shown to be an independent prognostic factor in PDAC.(112) Raman spectroscopy 
was able to attribute differences due to the twisting or wagging of CH3CH2 in collagen 
to identify differences between cancerous and normal tissue in both fresh and fixed 
tissue. Further identifying the degree to which this change was linked to the collagen 
alignment may be interesting further work. This could be achieved by comparing 
amide III to amide I ratio, which increases with increased collagen alignment and 
observing changes to the shape of the amide III band at 1270cm-1.(113) 
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Collagen is also thought to promote cancer cell survival, as nutrient-derived PDAC 
cells are shown to take up collagens through a number of mechanisms.(109) This 
collagen can be broken down to become a source of proline, which is used as a 
source of nutrients in glucose depleted conditions and is able to fuel tricarboxylic acid 
cycle metabolism to generate ATP.(109) This is in line with data from this study which 
shows that in fresh tissue there is separation of cancerous and healthy tissue due to 
differences in proline; confirming and providing some explanation for the likely 
increased presence of proline, as opposed to any other amino acid, in cancerous 
tissue where it is not present in healthy tissue. It also suggests that the variation seen 
in fresh tissue, as due to proline, and those seen in fixed tissue, as due to collagen, 
may be linked. This adds weight to the hypothesis that variation between cancerous 
and healthy tissue, seen in fixed tissue as due to collagen, may be a result of this 
variation being enhanced and highlighted by the alterations to collagen that occur 
during fixation.  
 
Sample preparation may have had impact on the variation seen between cancerous 
and healthy tissue, in fresh tissue due to peak 1662cm-1, indicating nucleic acid in 
tissue, as it is known that formalin fixation induces changes in nucleic acids.(85) Pre-
processed spectra show a lower intensity of the peak in healthy tissue and higher 
intensity in cancerous tissue, but a greater difference in intensity seen in fresh tissue 
than fixed. This suggests that this is an important change, but one which can only be 
identified using PCA in fresh tissue.  
 
7.2 Utility of Raman Spectroscopy in Identifying Cancer Stages and Healthy Tissue  
Comparison of scores plots of fresh tissue, with spectra classed by cancer type or by 
patient, shows that spectra thought to be taken from cancer overlap, regardless of 
which patient they are taken from. Spectra taken from normal and unknown tissue 
show much more difference between patients and are separate from cancer (Figure 
16b, Figure 18b). This overlapping, central section at the mean of PC1 may suggest 
that changes due to cancer are such that the natural variance between patients is 
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reduced as tissue becomes malignant, creating a tissue type that is more 
homogenous both within and between patients. It could be proposed that the 
natural variance between patients is overtaken by a greater variance between cancer 
and healthy tissue, due to structural change including the production of collagen and 
resultant production of proline as well changes to the nucleic acid presence in the 
tissue: this is highlighted by PCA.  
 
A comparison of the scores plots with spectra taken from tumour tissue identifies 
patient 4 as a very separate group (circled on Figures 7b and 8b), separating from all 
other tissue, regardless of whether this other tissue was cancerous, healthy or 
unknown, along PC2 in both fresh and fixed tissue. Also, as the tissue from patient 4 
was a core biopsy it was not possible to identify if the tissue was cancerous or 
healthy and so was all classed as unknown. Notably patient 4 had the most advanced 
tumour, at stage IIb, whereas patient 1,2 and 3 had stage IIa tumours.  This may 
suggest that Raman spectroscopy combined with PCA is able to identify a more 
advanced tumour, based on variations in collagen as well as DNA and lipid peaks. This 
strengthens the hypothesis that collagen is a structure which varies with the 
progression of pancreatic cancer and in a way which, using Raman spectroscopy, can 
be used to identify the presence and stage of the cancer.  
 
Differences between cancerous and normal tissue can be identified in both fresh and 
fixed tissue due to structural changes in the tissue but the identifying cause of the 
variation changes dependent on the method of sample preparation. Clinically this 
could have remarkable potential as it could mean that tumours could be staged more 
accurately pre-operatively, therefore reducing the number of patients who are found 
to have non-resectable tumours during surgery and be used intraoperatively to 
increase the number of complete resections.  Notably, at present it is also thought 
that 6-9% of pancreatic resections are done inappropriately for pancreatitis and so a 
more accurate preoperative method of diagnosis is imperative.(28) Equally, PCA 
shows there are still identifiable differences in fixed tissue which is useful for more 
thorough diagnosis of resection status and histologic type of the tumour after 
surgery, and for research purposes where it is useful to be able to preserve tissue.  
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The current method of identifying a tumour margin according to gross features of 
cancer, even with an experienced surgeon, is highly subjective and allows a high 
possibility of there being an incomplete tumour margin. One study indicated that if 
pathological assessment is detailed and standardized, margin involvement is found in 
>75% of pancreaticoduodenectomy specimens for pancreatic cancer.(114) 
Furthermore, there are difficulties in distinguishing between pancreatic, ampullary 
and distal bile duct cancers using histological methods, with frequent reclassification 
of the origin of the tumour, which also causes a wide range of rates of microscopic 
margin involvement in pancreaticoduodenectomy specimens, dependent on the 
pathological assessment.(105) This inconsistency in reporting means the clinical 
significance of margin involvement status in pancreatic cancer, and also ampullary 
and distal bile duct cancers, is unclear.(105) These difficulties in identifying both 
cancer type and tumour margins pose problems not only clinically for patients, as 
there can be uncertainty around diagnosis even after pathological assessment, but 
also for research as results are often compared to the current ‘gold standard’ of 
pathological assessment. Therefore, comparison of results between studies using 
human tissue could be of limited value.  
 
This presents an even greater need to identify a method of distinguishing between 
cancer types and identifying the tumour margin with much greater accuracy than is 
currently available, both intraoperatively and during histopathological assessment.  
Although a great deal of further work is needed, Raman spectroscopy could be a 
potential method by which this could be achieved, possibly by identifying the 
presence and changes to collagen in the tissue. In addition, the results of this study 
show promise for the application of Raman spectroscopy to blood samples, to 
identify between types of pancreatic cancer. 
 
7.3 Potential use of Raman Spectroscopy on Blood Samples  
Spectra taken from blood samples, both with and without the use of AuNP, showed 
extremely clear natural variance between patient samples, with no overlap of 95% 
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confidence ellipses. As there was a sample from each cancer type, it could suggest 
that some of the variance was the result of differences in cancer, although it is 
difficult to discern if the differences are due to the cancer types or the patients 
themselves. It is possible that both factors play a role. There are a number of 
clinically insignificant variables which may be causing this variance; the simplest and 
most likely of which is ABO blood typing, the status of which was unknown for all of 
the patients.  
 
A recent study showed variation between blood types using Raman 
spectroscopy.(115) However, laser tweezers Raman spectroscopy was used in order 
to achieve this result, in order to trap and manipulate cells in a way that would 
consistently exploit these differences, to avoid the impact of the Brownian motion of 
cells in an aqueous solution.(115) Conversely, the current study utilised this Brownian 
motion to acquire spectra from a range of components in the blood, thus reducing 
the impact any single variable related to a single component in the blood, such as 
ABO type, might have on variation. Despite including this variety of blood 
components in each sample, the spectra taken from each sample were very tightly 
clustered, with very clear separation seen between samples.  
 
Differences between blood type were seen as a decrease in Raman signal at 1224cm-1 
in blood type AB compared to other groups and changes to the shape of the spectral 
range at 1500-1700cm-1, including the 1620cm-1 n(C=C) bond.(115) These 2 peaks 
were the only ones suggested to contribute to differences in blood type, which 
overlapped with peaks identified on the PCA loadings plot from this study as causing 
variation between blood samples, indicating that the variations seen between blood 
samples are not just because of differences in blood type. Moreover, it was noted in 
the literature that the differences between Type A, Type B and Type AB are slight, 
whereas in the results, PCA identifies very significant differences between the 
samples.(115) 
 
Equally, each patients’ comorbid conditions, diet and the time of day at which the 
sample was taken, amongst other factors could add to the variation between the 
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samples. It is however, impossible to control for every potential factor and having 
more samples in the study may identify some of these confounders. Moreover, when 
blood samples are taken for clinical purposes, these factors cannot be controlled for 
and so identifying the degree to which the cancer contributes to the variation as 
opposed to the contribution of other factors would be important for clinical 
translation. The small sample size and lack of healthy controls or those with 
pancreatitis is a key limitation in this study, making it difficult to identify the degree 
to which this variation is disease specific. However, PCA evidently identifies clear 
variation between blood samples, in a way that cannot be attributed to blood type 
alone. Therefore, acquiring a larger sample size, including control samples, would be 
the next step in understanding the potential utility of Raman spectroscopy in the 
diagnosis of pancreatic cancer using blood samples and identifying which peaks in 
these spectra are specific to or due to pancreatic cancer.  
 
The PCA loadings plot for blood samples identified peaks at 1556cm-1 and 1563cm-1, 
as peaks which contributed to the variation between blood samples with and without 
the addition of AuNP. These peaks do not have a clear association in the current 
literature,(107) and the relative importance of these peaks in unknown. However, 
given that there has been considerable research on the use of Raman spectroscopy 
on blood, which has not identified these peaks, could suggest that these peaks are 
unique to blood samples taken from patients with pancreatic cancer and are 
substances which are being enhanced with the use of SERS.(116)  
 
In order to understand the utility of Raman spectroscopy and identify peaks which 
are specific to pancreatic cancer, it may be helpful to identify features which are 
similar between tumour tissue and blood. This would indicate if there are any 
molecules which are secreted by the tumour into the blood. PCA showed clear 
variation, with no overlap between a blood sample and tissue sample taken from the 
same patient, which is likely to be because there are significant differences between 
the samples as they are different types of tissue. Hence, it is likely that any secreted 
molecules make up a comparatively small part of the samples that their contribution 
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to the similarities in the spectra are masked by the great variation in other tissue 
components, especially using PCA which primarily identifies variation.  
 
7.4 Potential Biomarkers – SPARC and Collagen 
While it is currently possible to identify similarities and differences in a single known 
peak, this is dependent on first knowing which peak and associated molecule is linked 
to pancreatic cancer. SPARC has been shown to be present in tumour tissue and in 
serum samples, with an identified link between SPARC concentration in the serum 
and tumour size.(74) Therefore, it may be useful in further work to utilise Raman 
spectroscopy to identify and quantify the presence of SPARC in tissue and serum, as it 
is known that this is a molecule present in both samples. This would be comparable 
to quantitative ELISA testing and if able to be utilised would be a faster method of 
quantifying serum SPARC concentration, as the spectrum took only 10 minutes to 
acquire and required no sample preparation.  
 
Using the presence of SPARC, alongside the presence of collagen as identified in this 
study, may also create a highly specific marker for the tumour margin in pancreatic 
cancer.  Importantly, unlike collagen which is found in the basement membrane in 
healthy pancreatic tissue, there is no SPARC expression in the normal pancreas but 
this expression arises in invasive PDAC and remains throughout metastasis, although 
it is restricted to the stroma of the tumour.(50, 53) Therefore, using a combination of 
SPARC and collagen as important spectral features, may create a highly specific set of 
spectral markers to identify tumour margin. SPARC has also previously been 
identified as being upregulated in the initial stages of acinar destruction and lost in 
the final stages of acinar destruction and during acinar to duct metaplasia; events 
which are known to precede PanIN and PDAC.(52) Therefore, being able to identify 
the point of highest SPARC expression intraoperatively would also indicate the point 
at which metaplastic changes had begun and so indicate the edge of the resection 
margin, with greater accuracy, which may enable sufficient resection to the reduce 
the rate of recurrence of the disease.  
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This study has not found specific peaks associated or indicative of the presence of 
SPARC in the tumours. However, it has been identified by immunohistochemical 
staining, in the literature, suggesting the molecule is present in tumour tissue.(44, 49) 
SPARC also has a follistatin-like domain, which is rigidly stabilized by five disulphide 
bonds and contains a b-hairpin subdomain.(45) The presence of disulphide bonds 
may be able to characterise the molecule, however these are associated with a peaks 
at 509cm-1, 535cm-1 and 540cm-1, which was outside of the spectral range in this 
study. Therefore, there may be value in including this region of the spectral range in 
future work.   
 
7.5 Relationship Between HPAF-II cells and PSCs 
The presence of SPARC in cell line cocultures was also identified using quantitative 
ELISA. Identifying SPARC distribution, using immunohistochemistry, on the cell line 
cocultures would also have been an interesting comparison to the 
immunohistochemistry of the tumours and given information about the influence of 
different proportions of HPAF-II:PSCs on the expression and distribution of SPARC. 
However, in the current study the cells were inadequately fixed to the slides to 
enable immunohistochemical staining.   
 
Quantitative ELISA showed that HPAF-II cells did not produce any SPARC but that the 
presence of cancer cells was necessary for maximal SPARC production. This indicates 
that there is a complex relationship between HPAF-II cells and PSCs, requiring the 
presence but not the direct contact of both cell types to stimulate SPARC production. 
The complexity of the relationship between cancer cells and PSCs identified in the 
literature and the incompletely understood formation and role of stroma produced 
by PSCs is acknowledged as a remaining an area of difficulty in the development of a 
therapeutic target for pancreatic cancer.(12, 110) While PSCs are shown to enhance 
the malignant phenotype of cancer cells, removal of PSCs has been shown to 
promote pancreatic cancer in mouse models.(110)  
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The complexity of the relationship between HPAF-II and PSCs was also identified in 
data acquired from Raman spectra. Coculturing cells at any proportion created 
spectral differences in both HPAF-II and PSCs beyond the natural differences between 
uninfluenced HPAF-II and PSCs, suggesting there are biochemical changes to the cells 
themselves. In cocultures grown at HPAF:PSC 25:75 and 75:25 proportions, HPAF-II 
cells grown in indirect contact with PSCs showed complete separation from both PSCs 
and HPAF-II cells grown in direct contact with PSCs. This suggests that either the 
direct contact with PSCs causes cancer cells to acquire characteristics resulting in 
them becoming more similar to PSCs or that the indirect contact with PSCs induces a 
change in HPAF-II which is otherwise not present in direct contact between the cell 
types. While previous studies have identified that the cell culture supernatant from 
pancreatic cancer cells triggers production of ECM proteins and proliferation of PSCs 
and that culturing of cancer cells with PSC supernatant enhances rate of growth, 
proliferation and migration of cancer cells,(12, 103, 117) biochemical changes to the 
cells themselves have not previously been described.  
 
Activated PSCs are thought to produce 641 proteins, as opposed to 46 proteins 
secreted by quiescent PSCs, including matricellular proteins such as SPARC and a 
number of extracellular-matrix proteins, including collagen, stimulated by PDGF, TGF-
b and FGF-2.(103, 108) These growth factors are also able to promote the 
proliferation of cancer cells, through the activation of the Akt and MAPK signalling 
pathways, and are likely to have been present in the coculture media. (108, 117) 
Activation of PSCs has also been shown to be stimulated by growth factors, including 
PDGF, TGF-b and FGF-2, from injured acinar cells and cancer cells.(103) Hence the 
two cell types have a synergistic relationship where they are able to promote one 
another’s activation and proliferation.  
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Figure 39: Diagram created by H. Bham showing proposed interactions between HPAF-II 
and PSCs, drawing together processes from the literature. Quiescent PSCs (qPSC) are 
activated by platelet derived growth factor (PDGF), tumour growth factor-b (TGF) and 
fibroblast growth factor-2 (FGF).(103) Activated PSCs (aPSC), stimulated by PDGF, TGF and 
FGF secrete matricellular and ECM proteins, including collagen and SPARC.(49, 103) 
Presence of collagen and its contact with cancer cells increases Snail expression causing 
epithelial mesenchymal transition (EMT), which sensitises surrounding healthy tissue to 
tumour invasion, causing cancer cell proliferation.(110, 111)  Injured acinar cells (resulting 
from ADM and EMT) and cancer cells produce, PDGF, TGF and FGF causing further 
activation and proliferation of PSCs.(103) Physical presence  of collagen  and production of 
SPARC also slow proliferation of cancer cells, reducing the rate of cell turnover, meaning 
there are fewer biochemical changes to the cells.(47, 59, 110) 
 
However, recent evidence suggests that the presence of stroma and production of 
collagen, may have a protective role in pancreatic cancer.(45, 59, 64, 110) It is 
thought the production of collagen and fibrosis restricts the growth of the tumour. In 
order to do so, it may slow the proliferation of cancer cells, meaning fewer 
biochemical changes occur due to reduced cell turnover. This would mean that when 
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cells are grown in direct contact the presence of collagen slows the growth of cancer 
cells causing fewer changes to the cell (Figure 39). Cells grown in indirect contact with 
PSCs would still be exposed to growth factors in the shared media and so be able to 
proliferate as a result of the relevant signalling pathways, but without exposure to 
collagen meaning the growth of the cells would not be inhibited (Figure 39). This 
would create a higher rate of cell turnover and greater biochemical change, creating 
the variation seen on PCA between HPAF-II cells grown in direct and in indirect 
contact with PSCs. If the higher relative intensity of 1325-1345cm-1 peaks, compared 
to 600-800cm-1 peaks in the background of coculture maps suggest the possible 
beginnings of stroma formation, and so presence of collagen, this would corroborate 
the hypothesis. 
 
While this variation between HPAF-II cells grown in direct and in indirect contact was 
not seen in the 50:50 proportion, this may be explained by the production of SPARC 
seen on quantitative ELISA. The 50:50 proportion, in indirect contact produced the 
highest concentration of SPARC, which is thought to have a tumour suppressor 
function and has been shown to reduce the rate of cancer cell proliferation.(47) The 
presence of this tumour suppressor at this concentration in the media may have 
been sufficient to promote apoptosis and slow proliferation of the HPAF-II, even 
without the presence of collagen, for cells in indirect contact, preventing the 
biochemical changes from occurring to the same degree (Figure 39). Hence, 
cocultures in indirect contact at this proportion showed less variation than at other 
proportions.  
 
Comparison between cell line cocultures and cancerous tumour tissue, shows clear 
differences along PC3 are due to differences in carbohydrates and proteins, which 
suggests there are factors in vivo which create these differences that have not been 
replicated in this coculture study.  Although in vivo conditions are extremely difficult 
to replicate, especially in a 2D model, some of these differences may be caused by 
the lack of other important cell types such as tumour associated macrophages. (12) 
These cells have also been shown to be able to promote both an anti-tumorigenic 
and pro-tumorigenic response, which is thought to be dependent on the ratio of 
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tumour cells to macrophages.(12) PSCs have also been described as a heterogenous 
population, and this heterogeneity is unlikely to be reflected in a cell line model.(59) 
 
7.6 Strengths and Limitations  
This is the first study to use Raman spectroscopy on human tissue to identify 
variation between healthy and cancerous pancreatic tissue. It is also the first to use 
Raman spectroscopy and SERS without immunoassay on blood from patients to 
attempt to identify features which may be linked to the presence and type of 
pancreatic cancer. Although the study has a very small sample size and a lack of 
control blood samples, creating difficulty when drawing conclusions, it does identify 
variation between cancerous and healthy tissue, based on differences in nucleic acid 
content, proline and collagen. It further identifies clear natural variance in blood 
samples from different patients, with different types of cancer, which can be 
attributed to more than differences in blood type.  These observations have 
significant potential clinical utility if the results can be validated in a larger study.  
 
Previous studies have demonstrated properties and interaction of HPAF-II and PSCs in 
coculture, both in direct contact and culturing using the supernatant of the opposite 
cell type.(103, 117) However, this is the first study to coculture HPAF-II and PSCs in 
indirect contact, using an insert in a wells plate, creating an environment with 
concurrent presence and interaction but not the direct contact of the cells. It is also 
the first to identify variation and characteristics of the cells related to pancreatic 
cancer using Raman spectroscopy.  
 
The results of quantitative ELISA of SPARC, while comparable between cocultures of 
different proportions in the same environment, should be interpreted tentatively 
when looking at differences between cells grown in direct compared to cells grown in 
indirect contact. This is due to differences in the seeding density of cells, when 
setting up this experiment. Repeating this experiment, with cells seeded at the same 
density for both coculture in direct and indirect contact would give more comparable 
results.  
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The use of SERS and mapping images in comparing the impact of coculture could be 
of great value, as SERS extracted highly specific and varied spectra, which is likely to 
give very specific data about components of the cells.  However, the analysis of the 
data was very limited and the inability to compare between different maps offers 
limited comparison between cocultures of differing proportions and environments. 
 
7.7 Further Work  
7.7.1 Analysis of SERS data  
The difficulties in analysing SERS data because of the variety and single molecule 
sensitivity of spectra are described by Pavillion et al.(118) The SERS signal is 
dependent on the local presence and aggregation of nanoparticles and their 
interaction with the local molecular environment. Moreover, it is known that the 
‘best spectra’ are often not found where they might be expected in the AuNP 
distribution, even in the presence of nanoparticles.(118)  This means only a fraction 
of the data collected is of interest, and so there is a need to reduce the dataset to 
only include the relevant spectra to enable more specific analysis. 
 
An algorithm has been developed by Pavillion et al, which enables  detection, 
extraction and clustering of the most relevant SERS spectra, which are present on a 
localisation map.(118) The algorithm retains spatial information, making it possible to 
trace spectra from their location on the map, and has been used on live cells, 
showing its applicability to biological samples.(118)  While the information itself is of 
great value, the reduced dataset can also be used for further analysis such as 
PCA.(118)  
 
This algorithm could of great value when analysing the SERS maps from coculture 
experiments, allowing identification of pertinent similarities and differences in the 
spectra of individual components of the cells. There is an ongoing collaboration with 
authors of Pavillion et al 2013 to adapt the algorithm, making it compatible with SERS 
data from this study, to enable further analysis of the data.  
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7.7.2 Further experiments with Cocultures  
Given the identifiable differences between differing proportions of HPAF:PSC, 
extending this experiment to include more proportions, for example 90:10, would 
validate the impact PSCs have on HPAF-II cells and may identify the threshold at 
which this impact occurs. Using a variety of pancreatic cancer cell lines may also be 
valuable as the varying genotypes and phenotypes of the available pancreatic cancer 
cell lines have been shown to vary and give differing results when detecting 
tumorigenicity and angiogenesis.(119) The HPAF-II cell line is also a well 
differentiated cell line, from a 44 year old male with distant metastasis, unlike the 
patients in this study who were both older and had moderately differentiated 
tumours.(119) Using an additional cell line may therefore be of value, especially if the 
aim is to identify changes concurrent with the early interaction of PSCs and HPAF-II 
and their role in the development of PDAC, when patients would not have 
metastasis. The addition of tumour associated macrophages may also be valuable, as 
these have been shown to play an important role in tumorigenesis and have been 
shown to be viable in coculture.(120) The use of alternative cell lines and the addition 
of tumour associated macrophages may also make the cocultures more comparable 
to the human samples.  
 
Coculture of HPAF-II and PSC in this study appears to secrete ECM proteins, including 
collagen, which is identified as being of importance after data analysis, after the cells 
were grown for 7 days. This study proposes the hypothesis that interaction between 
the cell types and biochemical changes to the cells are possibly related to deposition 
of collagen and production of SPARC and their inhibiting effects on cancer cell 
proliferation (Figure 39). HPAF-II cells have also been shown to produce tumours in 
mice 100 days after orthotopic injection, however, it is likely that ECM production 
occurs much earlier than this.(119) Further work understanding when the ECM is 
produced, with a focus on collagen production and when it begins to have an impact 
on the cell characteristics would be valuable in further understanding the interaction 
between HPAF-II and PSCs. Scanning the cells at different time points during the 7 
days would also identify the point at which the most collagen is secreted and if this 
secretion is limited at any stage. Determining the timepoint at which the collagen 
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secretion and alignment is most similar to that in tumour samples would also help to 
validate any cell line model and understand its ability to function in a way similar to a 
tumour. Improving this functionality enables the production of cell line models which 
are closer to in vivo conditions, aiding the applicability and translation of research, 
such as drug testing, to clinical conditions and practice.  
 
7.7.3 Optimisation of Immunohistochemistry  
This study also attempted to identify SPARC expression from cell cocultures using 
immunohistochemical staining, however the cells were inadequately fixed to the CaF2 
slides to enable staining. This may in part have been a result of using CaF2 slides, 
which, although needed for optimum Raman spectra, are not ordinarily used for 
staining techniques. A previous study has however used alternative slides and 
clamped these to an aluminium plate to enable both immunofluorescence and 
Raman spectroscopy on the same sample of cells.(121) Another study has also shown 
potential for Raman spectroscopy of cells grown on polymer substrates such as agar, 
which may be particularly useful as these substrates are more able to imitate natural 
microenvironments such as ECM. (122) However, this is done by subtracting the 
Raman signal of the polymer substrate from the overall Raman spectrum, which may 
result in variable quality of the spectra. (122) 
 
These alternative methods may enable both immunohistochemical staining and 
Raman spectroscopy of cell cocultures, providing more information, particularly 
about the morphology of the cells, and a comparison between information identified 
by different techniques. However, it is known that the Raman signature from 
polymer substrates can create noise in the Raman signal,(122) and this limitation 
would need to be carefully considered and balanced with the advantages of growing 
cells on a polymer substrate.  
 
Moreover, the immunohistochemistry technique also needs to be optimised, for both 
cell samples and tumour tissue, as the SPARC antigen was not detected in the tumour 
tissue in this study. This may include altering the antibody dilutions, increasing 
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incubation periods and optimising antigen retrieval times as well as ensuring samples 
remain on the slides while being processed.  
 
7.7.4 Development of a SERS based Immunoassay 
The development of a SERS based immunoassay, identifying SPARC would also be 
valuable and an interesting comparison to histological techniques, in further research 
around the importance of SPARC, particularly in the early stages of pancreatic cancer. 
Such a development would also have great potential clinical utility, if SPARC was to 
be validated as a reliable marker for screening or diagnosis of pancreatic cancer. The 
development of nanoparticles, with improved sensitivity and specificity, for clinical 
use is already an extensive area of research and has been an essential part of the 
research around the use of Raman spectroscopy in other cancers.(123) It is also 
research which has attracted some attention in the use of Raman spectroscopy in 
pancreatic cancer, although the focus has largely been on the CA19-9 and MUC4 
biomarkers.(28, 92, 94) 
 
Another study, in mice, showed the potential to use injected SERRS nanostars to 
detect tumour margins at resections.(96) It identified that SERRS nanostars 
accumulated in the tumour stroma and within epithelial tumour cells and were also 
found in and able to identify PanIN lesions, showing high specificity for malignant 
tissues.(96) This suggests that pancreatic cancer lesions are able to take up SERRS 
nanostars and so a tumour margin could be identified very clearly in patients injected 
with these preoperatively. However, this uptake might vary between mice and 
human patients and require development of a nanoparticle which is both non-toxic 
and can be easily excreted, especially as it is known that some nanoparticles are 
toxic.(124) This could require significant work before there is potential for clinical 
translation. This study, however, demonstrates the potential of Raman spectroscopy, 
which is known to be safe in vivo, to differentiate between cancerous and healthy 
human tissue, without the use of nanoparticles, in pancreatic cancer. The 
development of a probe to detect these changes intraoperatively, would be an 
important step for translation to clinical practice.  
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7.7.5 Combining Clinical and Spectroscopic Techniques  
In the context of pancreatic cancer, combining spectroscopic techniques, including 
SERS and SORS with clinical techniques such as ERCP and endoscopy could allow for 
the development of a more sensitive or specific diagnostic technique. The potential 
for these techniques to be combined has been widely researched and the 
development of probes for clinical use is an ongoing field with great potential.(125) A 
probe, which can be attached to an endoscope, has been developed to detect 
changes in the oesophagus, suggesting there is potential to develop a similar probe 
for use in ERCP or EUS.(125) 
 
Conclusion  
Pancreatic cancer presents an increasing mortality burden, with few of the recent 
developments in treatment having a significant impact on the poor survival rates. The 
significant mortality burden can in part be attributed to difficulties in detection of the 
disease, during diagnosis, surgery and pathological assessment; 80% of cancers are 
diagnosed at an advanced and unresectable stage and 95% of cancers recur within 2 
years of resection.(1, 38) Lack of accuracy during histopathological assessment also 
causes problems for research as there is limited comparability between studies.(105) 
This presents a significant need for the advent of a new technology, with greater 
accuracy and potential clinical utility.  
 
Raman spectroscopy has been widely researched for its potential biomedical 
applications.(85) It has further been used in the detection and surgical guidance of a 
number of cancers, although its application to pancreatic cancer is very limited.(91)  
 
The aim of this study was to demonstrate the potential utility of Raman spectroscopy 
in identifying the development of pancreatic cancer and differences between healthy 
and cancerous pancreatic tissue.   
 
Using a 2D cell line model this study highlights the complexity of the relationship 
between cancer cells and PSCs. It identifies SPARC production using ELISA, showing 
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the need for the presence of both cell types for maximal production and suggests a 
role for collagen in inhibiting cancer cell proliferation. The interactions between 
HPAF-II and PSCs are thought to cause biochemical changes to cancer cells, which 
were identified using Raman spectroscopy. Cells grown in indirect contact showed 
greater variation than those grown in direct contact, with particular changes 
observed in cancer cells grown in indirect contact with PSCs. Although an unexpected 
result, the data from this study, alongside processes drawn from the literature, 
propose a hypothesis for the interaction between cancer cells and PSCs, suggesting 
that the physical presence of collagen may limit the rate of cancer cell proliferation 
and so the number of biochemical changes, due to reduced cell turnover. 
 
This study also demonstrates that Raman spectroscopy is able to differentiate 
healthy from cancerous tissue in the exocrine pancreas, using both fresh and fixed 
human tumour resection samples. It shows that cancerous tissue shows greater 
homogeneity both within the tissue itself and between patients. It could be proposed 
that this homogeneity is created by the deposition of collagen and natural variance 
between patients is overtaken by a greater variance characterised by the presence of 
collagen and identified by PCA. Moreover, this study suggests that Raman 
spectroscopy may be able to differentiate different stages of pancreatic cancer. 
Significant variation between blood samples from patients with different types of 
pancreatic cancer were also observed and, although patient characteristics are likely 
to play a role, part of this variation is thought to be attributable to the differences in 
cancer types.  
 
Although the small sample size is a significant limitation in this study,  this is the first 
study to demonstrate the potential utility of Raman spectroscopy in pancreatic 
cancer and therefore warrants further investigation. It demonstrates clear variation 
between cancerous and healthy tissue as well as significant variation between blood 
samples. Validating these results in a bigger study could be pivotal in utilising Raman 
spectroscopy to improve both the diagnosis and management of pancreatic cancer, 
to improve survival rates and reduce the mortality burden currently associated with 
the disease.   
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Figure 40: immunohistochemical staining of tumour tissue. The lack of a brown stain 
suggests no SPARC antigen was detected, suggesting the technique needs to be optimised. 
ai) patient 1 x10, aii) patient 1 x40 aiii) patient 1 x100 bi) patient 2 x10, bii) patient 2 x40 
biii) patient 2 x100 ci) patient 3 x10, cii) patient 3 x40 ciii) patient 3 x100 
 







Figure 41: white light images for cell cocultures with SERS showing cell outlines and 
presence of nanoparticles. Scale bar 20µm a) HPAF 25:75, b) HPAF 50:50, c) HPAF 75:25, 
d)HPAF 100% e) PSC 100% 
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ai)  aii)  
bi) bii)  
ci)  cii)  
di) dii)  
ei) eii)  
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Figure 42: Raman shaded maps for cell cocultures grown in direct contact with SERS 
showing shading by signal to baseline analysis  for wavenumbers i) 600-800cm-1 and 
ii)1325-1345cm-1. Colour bar shown as reference for shading; blue shows lowest relative 
intensity and red the highest relative intensity within the image but shading is arbitrary 
and not numerically equal or comparable between images. Scale bar 20µm. ai) HPAF:PSC 
25:75 600-800cm-1 shading aii) HPAF:PSC 25:75 1325-1345cm-1 shading , bi) HPAF 50:50 
600-800cm-1 shading bii) HPAF:PSC 50:50 1325-1345cm-1 shading, ci) HPAF:PSC 75:25 600-
800cm-1 shading cii) HPAF:PSC 75:25 1325-1345cm-1 shading, d)HPAF 100% 600-800cm-1 
shading dii)HPAF 100% 1325-1345cm-1 shading ei) PSC 100% 600-800cm-1 shading eii) PSC 
100% 1325-1345cm-1 shading
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ai) aii)  
bi) bii)  
ci)  cii)  
di) dii)  
ei) eii)  
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fi) fii)  
gi) gii)  
hi) hii)  
 
Figure 43: Raman shaded maps for cell cocultures grown in indirect contact with SERS 
showing shading by signal to baseline analysis  for wavenumbers i)600-800cm-1 and ii) 
1325-1345cm-1. Colour bar shown as reference for shading; blue shows lowest relative 
intensity and red the highest relative intensity within the image but shading is arbitrary 
and not numerically equal or comparable between images. Scale bar 20µm. ai) HPAF 25% 
600-800cm-1 shading aii) HPAF 25% 1325-1345cm-1 shading , bi) HPAF 50% 600-800cm-1 
shading bii) HPAF 50% 1325-1345cm-1 shading, ci) HPAF 75% 600-800cm-1 shading cii) HPAF 
75% 1325-1345cm-1 shading, d)HPAF 100% 600-800cm-1 shading dii)HPAF 100% 1325-
1345cm-1 shading ei) PSC 100% 600-800cm-1 shading eii) PSC 100% 1325-1345cm-1 shading, 
fi) PSC 25% 600-800cm-1 shading fii) PSC 25% 1325-1345cm-1 shading , gi) PSC 50% 600-
800cm-1 shading gii) PSC 50% 1325-1345cm-1 shading, hi) PSC 75% 600-800cm-1 shading hii) 
PSC 75% 1325-1345cm-1 shading. 
 
